ENDURANCEE N D U R A N C E 20082008 Progress Progress Report Report

pcf.org pcf.org

Finishing the Race pcf.org

The Prostate Cancer Foundation (PCF) was founded in 1993 to find better treatments and cures for prostate cancer. Through its unique model for identifying and selecting promising research programs and rapid deployment of resources, the PCF has funded more than 1,500 programs at nearly 200 research centers in 20 countries around the world.

As the world’s leading philanthropic organization for funding prostate cancer research, the PCF is now a foundation without borders. Its advocacy for increased government and private support of prostate cancer research programs has helped build a global research enterprise of nearly $10 billion.

In 2008, 40 percent fewer men in the U.S. died from prostate cancer compared to what was once projected in 1996. The PCF is a force of HOPE for more than 16 million men and their families around the world who are currently facing the disease.

With milestones achieved and challenges ahead, the work of the PCF is enduring. We remain committed to finishing a race that ends when death from prostate cancer is no longer an outcome.

Table of Contents Founder/CEO Letter 1 5-Year Revenue History 2008 Spending Connecting Cancer and 5 $ Millions $0.82 Prostate Cancer Research Mission Lifestyle 40 $37.2 $35.4 $0.76 $0.06 Advances in Prostate 6 35 Research Grants & Public Education Cancer Research: 2008 $31.1 Programs Support & Advocacy 30 $28.2 Challenge Awards 8 Young Investigators 10 25 $22.0 A Global Research 14 20 $0.11 Fundraising Enterprise 15

A Special Thank You 16 10 Appeal for Support 23 $0.07 5 Administration Donation Opportunities 24 0 Financial Statements 25 2004 2005 2006 2007 2008 Report of Independent 28 Auditors A Tribute to the Vinecki Family Board of Directors 29 This Progress Report is dedicated to the Vinecki family. Michael Vinecki was diagnosed with prostate cancer on and Leadership Team his 40th birthday in May 2008. Since then the family has worked tirelessly in support of prostate cancer awareness. Ten-year-old Winter (see cover photo) participated in the adult Athletes for a Cure Triathlon in September. She and Team Winter have helped raise more than $125,000 for advanced research. Michael lost his battle to cancer in March 2009. He and his family have touched many with their selflessness and caring. We are honored by their support. FINISHING THE RACE Endurance for Challenging Times

Dear Friends,

The Prostate Cancer Foundation (PCF) continues to lead •• Studies at ten U.S. sites of the Clinical Trials the fight against prostate cancer and give hope to Consortium, in partnership with the U.S. Department more than 16 million men and their families around the of Defense Congressionally Directed Medical world. Thanks to nearly 68,000 donors who contributed Research Programs (CDMRP). Since 2005, the Clinical Trials Consortium has initiated 44 clinical trials, Report Progress 2008 in 2008 to support our efforts, we finished the year enabling more than 1,600 patients to participate in able to commit more than $28 million toward specific the study of new medicines for prostate cancer. new research in addition to our existing research allocations. This will bring us closer to our goals of In 2009, the PCF continues to support its existing multi- ending suffering from prostate cancer and finding a year commitments and is funding ten new Creativity cure. Awards to support highly innovative ideas that would otherwise be left unfunded. Among other highlights in 2008, the PCF provided funding commitments for: The PCF’s model of venture philanthropy ensures that

•• Nine new multi-year Challenge Awards for scientific funds raised for research are distributed swiftly and teams, totaling $21.1 million efficiently to programs showing the most potential to accelerate the discovery and delivery of new therapies •• Twenty new three-year Young Investigator Awards for prostate cancer patients. totaling $4.3 million

2008 Milestones

1 Maintaining the Pace •• New biomarkers are being identified that can lead to better diagnostics and assessment of patient The number of new prostate cancer cases has risen response. with aging baby boomers, but the annual number of U.S. deaths has actually declined. This medical feat •• Innovative targeted therapies are being developed. could not have been accomplished without the work of •• Growing appreciation of the role of nutrition and PCF-supported researchers. But much work remains. exercise is leading to cancer prevention and Projections indicate there could be an unprecedented increased survivorship. number of new cases—300,000—and 42,000 deaths annually by 2015 if the death rate remains unchanged. Reaching Beyond the PSA Debate Fortunately, more progress has been made in the past Since 1980, PSA (prostate-specific antigen) screening, five years than in the first three decades following in combination with the digital rectal exam, has helped President Nixon’s declaration of the nation’s war on save many lives. However, because PSA testing can’t cancer in 1971: discern between highly aggressive, life-threatening •• We better understand gene fusions that cause and indolent (non-threatening) prostate cancers, prostate cancer. controversy continues around its use. While the screening has served us well as a general “smoke •• Research in immunotherapy—therapy to alert the detector” for prostate diseases, we’re supporting the body’s immune system to fight cancer—is advancing. development of better, cancer-specific diagnostic tests.

2008 Milestones

2 These include better technologies for collecting and Many men simply do not want to talk about medical identifying specific circulating tumor cells (CTCs) in problems that exist “below the belt.” To overcome this blood samples and prostate cancer-specific biomarkers problem, the PCF is developing more communication in urine. These are potentially transformational tools directed toward partners and wives, family breakthroughs that can save millions of lives while members, caregivers and younger audiences who are resolving the PSA debate. more open to the message of early detection and treatment. In the past year, the foundation has Building Public Understanding and widened its electronic communications by embracing

Government Support Report Progress 2008 new social media outlets, including Facebook and While the PCF’s primary mission is to support research, Twitter. a portion of our communications effort is focused on In our advocacy for increased prostate cancer research providing patients, families and caregivers the latest funding, the PCF identifies projects and researchers information on prostate cancer treatment options and that could benefit from federal funding. We recently lifestyle information. Our website, www.pcf.org, has joined forces with a coalition of prostate cancer attracted a growing following of patients, families and organizations to support continued 2010 donors. appropriations for the Department of Defense’s While prostate cancer is the second-most-common prostate cancer research programs. Members of the cancer in men, it remains one of the least discussed. PCF leadership team continue to participate on task

3 forces and committees that help shape public policy. human suffering from prostate cancer to an end. Since the PCF was founded in 1993, there has been a Thank you for your continuing support. twenty-fold increase in government funding for prostate cancer programs, and our bipartisan advocacy Sincerely, continues. The PCF represented the entire prostate cancer community—researchers, patients, families and healthcare providers—in the drafting process for the Kennedy-Hutchinson Cancer ALERT Act introduced in the U.S. Senate in early 2009.

One Team, Many Members One important measure of the PCF’s progress is the increased number of men who survived prostate cancer during 2008. This increase is the result, in large Mike Milken Jonathan W. Simons, MD part, of the remarkable teamwork of our donors, Founder and Chairman President and Chief Executive Officer scientists, patients, caregivers, staffers and others David H. Koch Chair whose lives are affected by this cancer. Together, we are bound to finish what we started in 1993: bringing

2008 Milestones

4 CONNECTING CANCER AND LIFESTYLE

The PCF has pioneered the field of diet and exercise as it relates to prostate and other cancers. The body of research linking good lifestyle choices to cancer survivorship, and perhaps prevention, continues to grow. Obesity, excess sugars, and cellular oxidation can foster prostate cancer growth. By stressing the importance of approaching prostate cancer through a commitment to lifestyle changes, the PCF’s guide on nutrition and exercise provides information that can help a man with (or without) prostate cancer build a stronger mind and body.

In 2008, the PCF updated the latest lifestyle guidelines for levels, one also lowers the body’s need to produce insulin, Report Progress 2008 prostate cancer patients and recently published an all-new a hormone which is needed to break down sugars. High publication: Nutrition, Exercise and Prostate Cancer. It is a insulin levels have been linked to an increased risk of complete reference for men and their families on the diabetes, heart disease, and prostate cancer growth, importance of exercise and proper nutrition. The guide independent of insulin’s interaction with sugar. was authored by a multidisciplinary team of world experts: Supplementing a balanced diet with multivitamins can be David Heber, MD, PhD, UCLA; Stephen J. Freedland, MD, a benefit, however, supplements must be used with Duke University; Lee W. Jones, PhD, Duke University; caution and do not compensate for a poor diet. Fruits and Jonathan W. Simons, MD William G. Nelson, MD, PhD, vegetables are rich sources President and Chief Executive Officer Johns Hopkins School of of mixed vitamins, David H. Koch Chair Medicine. minerals, antioxidants and The guide discusses the other specialized link between excess body substances that cannot be fat and a man’s chances of replicated in most developing prostate cancer supplements. Ultimately, by pointing to the fact that individuals should use wise body fat secretes judgment when hormones and specialized incorporating supplements proteins that are growth into their diet. factors for cancer. As Along with a proper diet, inflammation and incorporating daily exercise oxidation of cells occur, they become damaged, which can is paramount to preserving one’s overall health. Exercising contribute to prostate cancer development and aerobically for approximately a half hour every day (for progression. oxygen intake and to build muscle mass) has a positive Inflammation and oxidation of fat cells can be changed, impact on burning fat and increasing strength. however, by pointing one’s dietary focus toward eating As a person ages, the body’s metabolism slows down due fruits and vegetables, whole grains, and ocean-caught fish. to a decrease in muscle mass often caused by inactivity. Cruciferous vegetables, such as broccoli, are especially rich That is why it is vital for men to build and maintain muscle in sulforaphane that acts as a protective sponge against mass throughout their lifetime by eating adequate free radicals that cause oxidation. proteins and doing muscle-building exercises. Multiple studies have reported an increased incidence of Among other new 2008 findings highlighted in the guide, obesity and cancer in populations eating a Western diet. it was shown that exercise not only reduces and helps to Generally, with excess body fat higher levels of sugar are maintain weight but also curbs hunger, increases resting being consumed. This increased intake of sugar has been metabolism, increases bone density, and improves quality proven to fuel the growth of cancers, including prostate of life. The PCF continues to fund emerging science in the cancer. Substituting mixed berries and fruits for desserts area of nutrition. The guide provides readers with a high in sugar or eliminating soft drinks in favor of water balanced perspective on making wise choices with regard are just some ways to decrease sugar intake. to lifestyle and nutrition. A free copy of Nutrition, Exercise The guide recommends that by simply eliminating or and Prostate Cancer can be ordered or downloaded at lowering sugar intake, a man may slow prostate cancer cell www.pcf.org. growth and progression of the disease. By reducing sugar

5 ADVANCES IN PROSTATE CANCER RESEARCH: 2008

The complexity of prostate cancer demands investigation of the disease from numerous angles. In the past year, the PCF has witnessed game-changing advances in prostate cancer research accomplished by PCF-funded investigators working around the globe.

Scientific advances in the areas of genetics and genetic antigen in patients taking the drug after conventional anti- testing, immunotherapy, liquid biopsies, and androgen androgen therapy failed. receptor targeting offer hope that the impact prostate Developed by PCF-funded researcher Dr. Charles L. cancer has on millions of American men and their families Sawyers at UCLA, a protocol for a large-scale trial of will be diminished. But despite this progress, an American MDV3100 has been submitted to the U.S. Food and Drug man died every 19 minutes, leaving more than 28,000 Administration by Medivation Inc., a California-based families bereved in 2008. The PCF remains committed to biopharmaceutical company. improving diagnostics and treatment for prostate cancer patients, and further reducing the death rate. The human body possesses defense mechanisms to protect itself against harm, including cancer. The PCF has New Medicines for Advanced Prostate Cancer gone to great lengths to fund research in immunotherapy with the premise that stimulating the immune system’s Abiraterone Attracting global media coverage in 2008, ability to attack prostate cancer cells may be a viable Abiraterone was shown to be a promising medication for treatment option for patients facing this disease. prostate cancer. It has the potential to treat patients whose disease has relapsed using conventional medical Provenge® Investing more than $2 million to support treatment for advanced prostate cancer, including dendritic cell and immunotherapy research during the chemotherapy. past several years, the PCF was encouraged by recent data showing the ability of a new drug, Provenge, to increase PCF-funded researcher Dr. Gerhardt Attard and colleagues patient survival rates. Unlike most vaccines, Provenge is at the Institute of Cancer Research and The Royal Marsden not used to prevent illness but to treat an already existing Hospital, published findings in the Journal of Clinical condition. The vaccine combines an enzyme that is found Oncology detailing how the orally-administered drug in most prostate cancer cells with a protein that helps the works by blocking the pathways that drive prostate cancer. immune system recognize the cancer as a threat. Specifically, Abiraterone blocks the production of androgenic (male) hormones that contribute to the PCF-funded researcher Dr. Philip Kantoff, of the Dana- continued growth of prostate cancer. Farber Cancer Institute at Harvard Medical School, was the principal investigator of the Provenge Phase III clinical trial. The PCF Clinical Trials Consortium played an important The PCF provided early funding to Dr. Eric Small at UCSF role by accelerating U.S. clinical testing of Abiraterone in within the PCF Clinical Trials Consortium to support clinical Phase II clinical trials. These evaluations focused on the research focused on measuring immune response in drug’s anti-tumor action and were conducted in 132 patients treated with Provenge. The findings of Dr. Small patients at five leading prostate cancer centers that are all and his colleagues were published in the Journal of Clinical members of the consortium: Dana-Farber Cancer Institute Oncology in December 2000 and provided important at Harvard Medical Center, Johns Hopkins Cancer Center, contributions to the initial development of Provenge. M. D. Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center, and the University of California at San Francisco. The manufacturer of Abiraterone, Cougar Improved Diagnostics and Prognostics Biotechnology, was recently purchased by Johnson & While the PSA test remains an important tool for detecting Johnson. the possible presence of prostate cancer, it is not cancer- specific and is used in combination with other diagnostic MDV3100 This new therapeutic made headlines for its tools. This shortcoming has led to over-diagnosis and over- potential to improve outcomes for patients with hormone- treatment of some prostate cancer patients. The PCF is refractory cancer. This drug blocks the androgen receptor funding research to go beyond the PSA test and make for testosterone and other male hormones that help drive better diagnostics, prognostics and patient response tumor growth. One published journal report described measurements a reality. “sustained declines” in blood levels of prostate-specific

6 The ProvengeThe (sipuleucel-T) Process sarcosine to highly be elevated inmetastatic most prostate than 1,000 metabolites, and found the metabolite molecules, termed metabolites. team The more profiled identified links between prostate cancer and small disease. Their findings at the University of Michigan leadsoon to anon-invasive urine test for detecting the research on devising new prostate cancer diagnostics may Sarcosine patient responses during cancer treatment. treatment. The results could also allow doctors to monitor predict whether a tumor will respond to a specific microRNA profiling of apatient’s may blood able be to process once thought to impossible. be In the future, detection and measurement of microRNA in the blood—a Fred Hutchinson Cancer Research Center, studying the Army Creativity Award recipient, is leading at aproject the MicroRNA shorten the time required to test new medicines. for improved survival rates, and if they can be used to to determine whether CTC counts are a reliable biomarker a Phase III clinical investigation of Abiraterone. goal The is an aggressive prostate cancer. Quantifying CTCs is part of more than in 5CTCs 7.5 ml of is whole blood predictive of Hospital, respectively. Laboratory investigations show that Sloan-Kettering Cancer Center and The Royal Marsden HowardDrs. Scher and Johann of DeBono Memorial from prostate cancer patients have been investigated by disease progression in patients with solid tumors. CTCs other PCF-funded researchers to survivaland predict computer chips. This technology is now being utilized by processes similar to those used for manufacturing microfluidic device (see photo, page 8) is produced using using a microelectromechanical system (MEMS). The tool to collect and count rare circulating tumor cells (CTCs) Massachusetts General Hospital in Boston developed a TumorCirculating Cells (CTCs) Illustration courtesy of Dendreon™ of courtesy Illustration from thepatient. whiteblood cellsarecollectedcollection; The patientgetsstandardblood Leukapheresis Day 1

Drs. Arul Chinnaiyan and Arun Sreekumar’s In Seattle, Dr. Muneesh Tewari, a PCF Arnie’s Dr. Daniel Haber at Cassette for approximately 40hours. APCs arecombined with Dendreon’s AntigenDelivery technology.white bloodcellsusing proprietary Antigen presentingcells(APCs)areseparated fromother PROVENGE (sipuleucel-T) ismanufactured Days 2-3 biomarker of prostate for asubtype cancers. Dr.needed, Tomlins’ finding may have identified anew ETS gene fusions. Although additional investigation is This gene is present in prostate cancers that do not have cancer and plays a role in at least 50 percent of patients. inhibitor, Kazal 1). type It is highly expressed in prostate discovering a gene called SPINK1 (serine peptidase Scott Tomlins made headway in genetic research by SPINK1 prostate cancer can more be readily projected. based SNP tests now available, the odds of developing men with prostate cancer compared to others. With saliva- studied for potential “hot spots” of differences in genes of genetic diversity), such as Sweden. DNA was collected and SNPs is ideal in countries with little ethnic diversity (i.e. prostate cancer ten-fold. Identifying disease-associated dramatically raise the lifetime risk of being diagnosed with singlenucleotide polymorphisms(SNPs)—that discovered a combination of five gene variants—called Sweden were published by PCF-funded scientists who SNPs Markers Assessment Risk New laboratory findings. results from these molecular tests with other clinical and diagnosis and prognosis will likely increase by combining 2008 Scientific Retreat at Lake Tahoe that information on cancer-associated gene. Dr. Schalken noted at the PCF’s research to the detect presence seeks of PCA-3, aprostate molecular diagnostic test of urine for prostate cancer. His in the Netherlands is also working on developing a PCA-3 targets and diagnostic biomarkers. metabolites as tools for developing new therapeutic cancer urine samples. The team’s goal is to use

In 2008, notable findings out of the U.S. and Dr. Jack Schalken from the University of Nijmegen PCF Young Investigator Award recipient Dr. Complete courseoftherapy: 3cycles intravenously The physician administersPROVENGE Pa Days 3-4 tient isinfused . 7

2008 ProgressProgress Report Report A circulating tumor cell (CTC), captured on the nano-sized post ofpost a microfluidic device, is depicted in yellow. in is depicted 8 105 cancer programs in 11 countries. These multi-year programs with high potential will receive three annual payments, James Allison, PhD, Memorial Sloan-Kettering Cancer Center Cancer Sloan-Kettering PhD, Memorial Allison, James The team’sThe genetic biotechnologies in research a significant drug discoveryapplies state-of-the-art effort Todd R. Golub, MD, Broad Institute of MIT and Harvard and MIT of Institute MD, Broad Todd Golub, R. CTLA-4 Blockade in Therapy of Prostate Directions of Therapy New in Mechanisms and Blockade Cancer: Therapeutic CTLA-4 Without PCF funding, these teams would not have the resources necessary to move Discovery of Inhibitors of TMPRSS2/ERG of Inhibitors of Prostate in Function Discovery Cancer Epigenetic Strategies in Androgen Receptor-Dependent Interchromosomal Networking and Translocation and InterchromosomalNetworking Events Receptor-Dependent Strategies Androgen in Epigenetic Challenge Awards in addition to the Koch-PCF Nanotherapeutics Challenge Award. saving medication for prostate cancer patients. cancer prostate for medication saving their work forward. A record 113 teams proposed new hypotheses and approaches in cancer to cause the elimination ofof tumors. Aimmunotherapeutic variety strategies for the treatment of changes resulting in prostate cancer. overallThe ofobjective Dr. Rosenfeld’s work is to discover new team propose toexpert apply new genetic biotechnology toward the discovery of genetic and epigenetic to expression gene linking discoveries important generated has study of area new changes). relatively This In 2008, the Prostate Cancer Foundation committed more than $19 million for eight new Recipients of PCF Challenge Awards were chosen by an expedited peer review William C. Hahn, MD, PhD, Dana-Farber Cancer Institute, Broad Institute of MIT and Harvard and MIT of Institute Broad Institute, Cancer MD, PhD, Dana-Farber Hahn, C. William committee of 52 skilled scientific and milestones clinical Specific are experts. outlined Medical School to evaluate ETS factor inhibitors discovered in this work for the goal of developing alife- developing of goal the for work this in discovered inhibitors factor ETS to evaluate School Medical programs can found be at by the foundation for yearly review, and research teams are required to share their biotechnology that could significantly reduce prostate cancer deaths. They represented ranging $500,000 between and $1.0 million each. prostate cancer are being developed. There is a significant need for discovery of blood markers that will will that markers blood of discovery for need is asignificant There developed. being are cancer prostate have failed. treatments existing all when cancer prostate control that medications MD, Rosenfeld, Michael G. of University California, San Diego the development of cancer, and has proven to be vital to prostate cancer research. Dr. Rosenfeld and his his and Dr. research. Rosenfeld cancer to prostate cancer, vital of to proven be has and development the findings at the PCF’s annual Scientific Retreat. A full description of these Challenge Award to target ETS factors produced by prostate cancer cells. Collaborators at the Broad Institute of MIT and and MIT of Institute Broad at the Collaborators cells. cancer by prostate produced factors ETS to target cancer. prostate of growth the arrest will factors ETS of activity the block that medications of discovery the In recent years, scientists have discovered that a specific genetic rearrangement in normal prostate cells cells prostate normal in rearrangement genetic have aspecific that discovered scientists years, recent In Immunotherapy is a form of treatment that involves directing a patient’s immune response against their their against response immune apatient’s involves that directing treatment of is aform Immunotherapy Epigenetics is the study of gene control by mechanisms other than changes in gene sequence (genetic (genetic sequence gene in changes than other by mechanisms control gene of study is the Epigenetics Harvard are Harvard working withand atoncologists biologists the Dana-Farber Cancer Institute at Harvard IMMUNOTHERAPY ETS GENE FUSIONSETS GENE EPIGENETICS Levi A. Garraway, MD, PhD, Dana-Farber Cancer Institute, Broad Institute of MIT and Harvard and MIT of Institute Broad Institute, Cancer Garraway, MD, PhD, A. Dana-Farber Levi Padmanee Sharma, MD, PhD, M. D. Anderson Cancer Center Cancer MD,D. PhD, M. Anderson Sharma, Padmanee leads to ofthe cancerproduction promoting(ETS factors) infactors prostate cancer. It is presumed that CHALLENGE AWARDS CHALLENGE www.pcf.org .

2008 Progress Report 2008 Progress Report As the removal of testosterone and other male hormones (androgens) is currently the best available treatment for advanced prostate cancer cancer prostate advanced for treatment available best (androgens)the is currently hormones male other and testosterone of removal the As Clinical and Biological Insights into Prostate Cancer Derived from the Microfluidic Capture of Circulating Captureof Tumor Insights into Prostate Biological Clinical and Microfluidic the Cells from (CTCs) Cancer Derived Relevant Prostate of Analysis and Systems Cancer Development the Model for Consortium Synergistic Targeting Prostate in Metabolism Androgen Cancer AR and of Defining Targets Prostate in Biomarkers and CancerDefining Stem Opportunities Cells: Therapeutic New Prevention of Treatment and Disease-Related Morbidity During Androgen Deprivation Therapy: A Multi-Center Proposal AMulti-Center Therapy: Deprivation Androgen During Prevention Treatment Morbidity of Disease-Related and Steven P. Balk, MD, PhD, Beth Israel Deaconess Medical Center Medical Steven P. Deaconess Israel MD, PhD, Beth Balk, evaluation of advanced immunotherapies and rigorous molecular analysis of patients’ response to immunotherapy. The goal is to use these these is to use goal to immunotherapy. The response patients’ of analysis molecular rigorous and immunotherapies advanced of evaluation organized a national consortium of expert investigators that intend to better characterize existing models of prostate cancer and determine determine and cancer prostate of models existing characterize to better intend that investigators expert of consortium anational organized carefully studying androgen reduction in tumor tissue from patients treated with a new generation of androgen production inhibitors to to inhibitors production androgen of generation anew with treated patients from tissue tumor in reduction androgen studying carefully determine the mechanism of inhibition. Since it is likely that patients will ultimately become resistant to the new medications, of identification define this define critical tumor cell population and reveal new therapeutic targets. Cancer stem cells are an elusive, small subpopulation of tumor cells that are not only resistant to therapy but also repopulate a solid tumor after after tumor asolid repopulate also but to therapy resistant only not are cellsthat tumor of subpopulation small elusive, an cellsare stem Cancer MD, UCLA Witte, N. Owen and progression of prostate cancer. Medications that reduce androgens cause clinical remission invariably followed by disease progression. It is priority for the PCF. These markers will increase the pace of drug development and warn physicians earlier when prostate cancer is progressing. is progressing. cancer prostate when earlier physicians warn and development drug of pace PCF. the the for increase will markers These priority models suitable for preclinical assessment of new, experimental medications for advanced prostate cancer. prostate advanced for medications new, of experimental assessment preclinical for suitable models patients with advanced prostate cancer. prostate advanced with patients patients; the medications used to reduce androgen in patients can illness.cause significant secondary Dr. Smith and his U.S./Canada team of Center Cancer Hospital General MD, PhD, Massachusetts Smith, R. Matthew are Nelson and Kantoff Balk, Drs. progression. disease for cause is one tissue,which tumor within produced be can androgens that known now research. Dr. Witte and his team at UCLA and the Salk Institute of Biological Studies are world leading experts in cancer stem cell biology. This This biology. cell stem cancer in experts leading world are Studies Biological of Institute Salk the and at team his UCLA and Dr.research. Witte cancer in is apriority elimination their targeting cellsand stem cancer of biology the by atherapy. Understanding killed cellsare tumor most where the gaps are in our ofunderstanding the disease pathology. are bydeficiencies The being corrected the creation of a new generation of these negative consequences. Dr. Smith’s expert team is currently investigating how to limit obesity, diabetes, bone fractures and heart disease disease heart and fractures bone diabetes, obesity, to how limit investigating is team currently Dr. Smith’s consequences. expert negative these the mechanisms of resistance will help identify the next generation of prostate cancer treatments. treatments. cancer prostate of generation next the identify help will resistance of mechanisms the team is currently directing their expertise toward studying prostate cancer stem cells. Application of new genetic biotechnologies will better better will biotechnologies genetic new of Application cells. stem cancer prostate studying toward expertise their directing isteam currently in patients treated for advanced prostate cancer. Exercise, nutrition and new medications are being employed to enhance the health of these to prevent made be can interventions medical where to determine deprivation androgen of consequences health the studying are investigators Preliminary findings suggest that enumeration of these cells provides an early signal of disease progression. These will be clinically validated. clinically be will These progression. disease of signal early an cellsprovides these of enumeration that suggest findings Preliminary blood. patient cellsin tumor measures that asystem to refine is working engineers, and biologists oncologists, with Dr. Haber, collaboration in is a cancer prostate for medication experimental an of effectiveness the signaling or progression disease predicting for biomarkers of Discovery Laboratory models that reflect prostate cancer models that clinical reflect areforLaboratory investigatingbiology important new treatments for the disease. Dr. Vessella has For advanced prostate cancer patients, the availablebest treatment is the removal of testosterone (androgens)hormones that drive the growth INTRACRINE ANDROGENS AND ANDROGEN RECEPTOR SIGNALING RECEPTOR ANDROGEN AND ANDROGENS INTRACRINE PROSTATE CELLS STEM CANCER PROGRESSION BIOMARKERS MODELS PRECLINICAL PREDICTIVE METABOLISM PATIENT AND NUTRITION, LIFE OF QUALITY herald an anti-tumor response as well as warn of an impending adverse event due to the therapy. Drs. Sharma and Allison are performing clinical clinical performing are Allison and Sharma therapy. to event the due Drs. adverse impending an of aswarn aswell response anti-tumor an herald Daniel Haber, MD, PhD, Massachusetts General Hospital Cancer Center Cancer Hospital General Haber, MD, PhD, Massachusetts Daniel Washington of MD, University Vessella, L. Robert Peter S. Nelson, MD, Fred Hutchinson Cancer Research Center, University of Washington of Center, University Research Cancer MD, Hutchinson Fred Nelson, S. Peter Institute Cancer MD, Dana-Farber W.Philip Kantoff, findings toandfindings safer immunotherapeuticdevelop moretreatments effective for prostate cancer.

9

2008 Progress Report YOUNG INVESTIGATORS

Designed to encourage the most innovative research thinkers to continue their careers in prostate cancer research, the PCF’s Young Investigator Award program is for young, early-career scientists. Consistent with our goal to end death and suffering from prostate cancer, these awards focus our efforts on developing human capital and a world-class community of investigators to undertake the next generation of prostate cancer research.

These awards provide $75,000 per year for three years to support specified research programs. The total $225,000 award amount is matched by each recipient’s institution, providing a total investment of $450,000 in each innovative research area. Funds may be used flexibly to advance the career and research efforts of the recipients. Mentorship is required for every PCF Young Investigator. Young Investigator awardees and their mentors are invited to participate in the PCF’s Annual Scientific Retreat.

Starting with the initial funding cycle in 2008, the PCF intends to fund 100 Young Investigators over the next few years. In 2008, the foundation received 76 applications from eight countries in North America, Europe and Asia, focused on 16 different prostate cancer research areas. Following peer review, the PCF committed a total of $4.3 million to the first 20 Young Investigator Awards. More detailed information on these Young Investigators is available in the research section of our website at www. pcf.org.

THE GOERGEN FOUNDATION - PCF YOUNG INVESTIGATOR AWARD Andrew Armstrong, MD, ScM Duke University Dr. Armstrong is working to discover biomarkers that will identify patients with prostate cancer who are at higher risk for a more aggressive clinical progression of the disease. Molecular markers to predict metastasis will be studied on circulating tumor cells—the small proportion of prostate cancer cells that “break away” from the primary cancer and enter blood circulation. Patients presenting these markers might be treated aggressively at an earlier stage of disease.

MICHAEL MILKEN SCHOLAR - PCF YOUNG INVESTIGATOR AWARD Mohamed S. Arredouani, PhD Beth Israel Deaconess Hospital Immunization of patients to generate an immune response to eliminate cancer is an increasingly important therapeutic strategy for advanced prostate cancer. Dr. Arredouani hopes to develop a new generation of prostate cancer vaccines with molecules known to be involved in the malignant transformation of prostate cells. Two such molecules have been selected and will be tested.

THE SUSAN AND JAMES BLAIR - PCF YOUNG INVESTIGATOR AWARD Gerhardt Attard, MD, PhD The Institute for Cancer Research (London) Inhibition of CYP17 by Abiraterone has promising anti-tumor activity in advanced prostate cancer. This experimental medication blocks the production of the “gasoline” that fuels cancerous tumor growth. Nonetheless, 50 percent of chemotherapy-treated patients do not respond to Abiraterone from the outset, and the majority of patients eventually develop acquired resistance. Circulating tumor cells are being studied to identify a biomarker profile that predicts which patients might be sensitive to Abiraterone and those that might become resistant.

THE ROBBINS FAMILY - PCF YOUNG INVESTIGATOR AWARD Tarek Bismar, MD University of Calgary A specific gene fusion of pieces from two different chromosomes is present in 50 percent of prostate cancers and is thought to drive the disease. In addition, a normal protein named PTEN suppresses tumor development unless genetically altered as is the case in many advanced prostate cancer cases. Dr. Bismar is studying both of these changes in model systems in an attempt to discover how together they deregulate the control of growth and survival that result in prostate cancer.

10 Johns Hopkins University Hopkins Johns The University of Texas M. D. Anderson Cancer Center Cancer Texas of D. M. Anderson University The The University of Texas M. D. Anderson Cancer Center Cancer Texas of D. M. Anderson University The

Adam Feldman, MD Feldman, Adam THE EARLE I. MACK YOUNG I. -PCF INVESTIGATOR EARLE THE AWARD YOUNG -PCF INVESTIGATOR INCORPORATED AWARD GEN-PROBE THE KOVLERTHE FAMILY FOUNDATION YOUNG -PCF INVESTIGATOR AWARD YOUNG -PCF INVESTIGATOR AWARD GRAUER LAURIE AND PETER THE Steven Frank, MD Steven Frank, PhD Dehm, M. Scott Steve MD Cho, compared to benign prostate cells. Dr. Feldman hopes to discover these differentially expressed proteins proteins expressed differentially to discover these Dr. cells. hopes Feldman prostate to benign compared cancer clinical trials with the ofobjective monitoring tumor volume changes during experimental or pads for up to two years following their treatment. Dr. Frank’s goal is to eliminate incontinence in men men in Dr. incontinence is to eliminate Frank’s treatment. goal their following years to up two for pads or to cause AR continues the how reflect that to models create Dr. is attempting Dehm progress. can cancer determination, cancer cure rates will increase and side effects will decrease translating into an into an translating decrease will effects side and increase will rates cure cancer determination, data reveals that up to 33 percent of men or approximately 73,000 men annually will be wearing diapers diapers wearing be will annually men 73,000 approximately or to reveals up that 33 men of data percent so-called This androgens. of action or production the of blockade asystemic via treated may be disease androgen levels in the area of prostate cancer bone metastases to determine if androgens are are androgens if to determine metastases bone cancer prostate of area the in levels androgen is measuring Dr. years. Efstathiou few next the in cancer prostate advanced for care of a standard androgen ablation therapy specifically inhibits the androgen receptor (AR), a receptor that drives the the (AR), drives that receptor areceptor androgen the inhibits specifically therapy ablation androgen MICHAEL MILKEN SCHOLAR - PCF YOUNG -PCF INVESTIGATOR AWARD SCHOLAR MILKEN MICHAEL undetectable, as is the case in tumor tissue from other sites, when total androgen suppressive suppressive androgen total when sites, other from tissue tumor in case asis the undetectable, membrane-associated and secreted proteins are differentially expressed by prostate cancer cells cells cancer by prostate expressed differentially are proteins secreted and membrane-associated Center Cancer Hospital General Massachusetts medications are administered. It is thought that these studies will help determine which patients could membrane antigen (PSMA) is expressed on the surface of prostate cancer and represents a promising apromising represents and cancer prostate of surface the on (PSMA) is expressed antigen membrane proliferation and survival of prostate cancer even after androgen synthesis and activity are blocked. are activity and synthesis androgen even after cancer prostate of survival and proliferation prostate and curative, is not cancer. However,ablation prostate of androgen survival and proliferation Minnesota of Center, Cancer University Masonic this project is to correlate biomarker findings with prostate cancer diagnosis, grade and pathologic stage. stage. pathologic and grade diagnosis, cancer prostate with findings biomarker is to correlate project this treatment. target PSMA with higher PET imaging resolution. Dr. Cho is characterizing this PET tracer in prostate should radiotracers PET molecule small weight, molecular Lower imaging. PET cancer prostate for target treated with brachytherapy by using MRI image-guided radiation therapy. With accurate dose dose therapy. accurate With radiation image-guided MRI by using brachytherapy with treated in urine, delivering a non-invasive practical biological fluid for biomarker discovery. The second goal of of goal second discovery. The biomarker for fluid biological practical anon-invasive delivering urine, in improvement in quality of life following treatment. following life of quality in improvement to developed been has agent imaging PET radiotracer molecule Asmall detection. tumor improve solid In the event that surgery or radiation does not curtail prostate cancer, locally recurrent or metastatic metastatic or recurrent cancer, locally prostate curtail not does radiation or event surgery that the In New biomarkers for improved detection and prognosis of prostate cancer are needed. Intracellular, needed. are cancer prostate of prognosis and detection improved for biomarkers New New experimental Newdrugs experimental that androgen shut(the off forfuel prostate cancer) synthesis will likely become New methods to image prostate cancer at the microscopic level are urgentlyProstate-specific needed. Following prostate cancer treatment, men are embarrassed if often they become incontinent. Recent Eleni Efstathiou, MD, PhD Efstathiou, Eleni benefit from or be resistantbenefit to these new medications. 11

2008 ProgressProgress Report Report THE JOY AND JERRY MONKARSH FAMILY FOUNDATION - PCF YOUNG INVESTIGATOR AWARD Isil Guney, PhD Dana-Farber Cancer Institute Prostate cancers are initially dependent on androgens for survival and androgen-ablation therapies comprise the only effective treatment for metastatic disease. Eventually, however, prostate tumor cells acquire the capacity to survive and proliferate at exceedingly low levels of circulating androgens. Such hormone therapy-resistant prostate cancers are incurable. A thorough understanding of the molecular events that promote the development of hormone resistance in prostate cancer is necessary for the design of effective therapies for patients with hormone- resistant disease. Dr. Guney is working to identify molecules that are suitable for development as therapeutic targets in advanced prostate cancers.

THE NEUBAUER FAMILY FOUNDATION - PCF YOUNG INVESTIGATOR AWARD Thomas Guzzo, MD University of Pennsylvania Dr. Guzzo is creating a prostate cancer translational research unit within the urology division at the University of Pennsylvania. Dr. Guzzo is focusing on clinical outcomes to improve surgical results for men diagnosed with early prostate cancer that include novel approaches to reducing morbidity from surgery.

THE DEFEO FAMILY - PCF YOUNG INVESTIGATOR AWARD Andrea Harzstark, MD University of California at San Francisco Immunotherapy offers the potential to stimulate a prostate cancer patient’s immune response to kill a growing tumor. Unfortunately, cancer cells are very weak vaccine agents alone, and require other co-therapeutic strategies to be effective. Dr. Harzstark is working to enhance the immune response to prostate cancer with a variety of approaches that might result in elimination of tumors.

PCF YOUNG INVESTIGATOR AWARD Sarah Holt, PhD Fred Hutchinson Cancer Research Center Carcinogenic effects of estrogen on the prostate have been demonstrated in laboratory models. There is a current resurgence of interest in using synthetic estrogens to treat patients with advanced prostate cancer. Dr. Holt is studying genetic alterations in genes responsible for estrogen sensitivity and metabolism in the prostate of 1,457 prostate cancer patients compared to 1,351 control subjects without prostate cancer. Results should help identify patients with increased risk for primary prostate cancer and those who might develop a more aggressive form of the disease.

MICHAEL MILKEN SCHOLAR - PCF YOUNG INVESTIGATOR AWARD Lorelei A. Mucci, ScD, MPH Harvard School of Public Health A recent finding in prostate cancer biology is the existence of specific gene fusions of chromosomes in disparate regions of a patient’s genome. These gene fusions give rise to expression of molecules with strong cancer-causing properties. Emerging data suggest men with tumors that lack the fusion have an improved prognosis compared to men with fusion-positive prostate cancer. Dr. Mucci is studying 1,500 prostate cancer patients to understand the relationship of the gene fusions to hormonal balance, energy balance, and healthy weight. The impact of these physiological properties on patient survival will be determined.

THE WILLIAM L. EDWARDS - PCF YOUNG INVESTIGATOR AWARD Mark Pomerantz, MD Dana-Farber Cancer Institute During the past two years, genomic scans have identified the genetic basis of prostate cancer risk. Dr. Pomerantz is looking to determine the molecular basis of increased prostate cancer risk in individuals that possess the genomic alterations. Understanding these mechanisms of risk may lead to new targets to inhibit the progression of prostate cancer.

12 “gasoline” that fuels the growth and progression of prostate cancer. Despite frequent responses, tumors J591 is a monoclonal antibody against prostate-specific membrane antigen (PSMA), a molecule on the the on (PSMA), antigen amolecule membrane prostate-specific against J591 antibody is amonoclonal Therapies that down-regulate ARs using novel mechanisms, have a tremendous potential to introduce to introduce potential have atremendous mechanisms, novel using ARs down-regulate that Therapies The androgen receptor (AR) system plays a central role in prostate cancer and represents a critical target target acritical represents and cancer prostate in role acentral plays (AR) system receptor androgen The THE L THE YOUNG -PCF LEE INVESTIGATOR H. AWARD THOMAS THE FOUNDATION YOUNG DURDEN -PCF THE INVESTIGATOR AWARD Ganesh Raj, MD Raj, Ganesh Specific chromosomal Specific rearrangements in more than half of prostate cancers, using a unique analysis of Scott Tomlins, PhD Scott Tagawa,Scott MD surface of prostate cancer cells. Studies using J591 linked to radioisotopes (radioimmunotherapy, RIT) have J591 using Studies (radioimmunotherapy, RIT) cells. cancer to prostate radioisotopes of linked surface of high oxidation. high of genes in prostate cancer. prostate in genes early the for Dr. tests diagnosis. Tomlins for developing on used be is focusing can also and therapy cancer cancer to determine the dosage and optimal administration schedule required to effectively treat the the treat to effectively required schedule administration optimal and dosage the to determine cancer cancer therapy, including tumor-specific vaccines and immuno-enhancing agents. Dr. Redmond hopes to to hopes Dr. Redmond agents. immuno-enhancing and vaccines tumor-specific therapy,cancer including combine an MR imaging agent and a drug delivery vehicle for gene-targeted inhibitors. Specific gene gene Specific inhibitors. gene-targeted for vehicle delivery adrug and agent imaging MR an combine develop a new method for finding better tumor markers that herald prostate cancer progression in a state astate in progression cancer prostate herald that markers tumor better finding for method anew develop diagnosis of prostate cancer using these gene fusions as well as characterizing additional dysregulated dysregulated additional ascharacterizing aswell fusions gene these using cancer prostate of diagnosis disease. metastatic in disease of sites known to target ability asthe aswell efficacy and safety demonstrated delivery of these new inhibitors to their targets is difficult. Dr. Raj’s goal is to refine a system that will will that asystem Dr. is to refine Raj’s goal is difficult. targets to their inhibitors new these of delivery almost always recur with subsequent activation of the androgen receptor (AR), the target for testosterone. testosterone. for (AR), target receptor the androgen the of activation subsequent with recur always almost are normally located on separate chromosomes. These gene fusions become rational targets for prostate prostate for targets rational become fusions gene These chromosomes. separate on located normally are Weill Cornell Medical College Medical Cornell Weill William L. Redmond, PhD Redmond, L. William Metastatic prostate cancer is treated with androgen deprivation therapy that reduces testosterone, the the testosterone, reduces that therapy deprivation androgen with is treated cancer prostate Metastatic UT Southwestern Medical Center Medical Southwestern UT University of Michigan of University UT Southwestern Medical Center Medical Southwestern UT new treatments and improve the outlook for prostate cancer patients. Dr. is Sharifi working to determine if prostate cancer. Dr. Tagawa is furthering clinical investigations of J591 in patients with advanced prostate prostate J591 of cancer. investigations Dr.advanced prostate clinical with Tagawa patients in is furthering the down regulation of certain antioxidants will over activate AR function. Her second objective is to objective second Her AR function. over activate will antioxidants certain of regulation down the targets are the AR and AR-associated molecules. AR-associated AR and the are targets immunostimulators. DNA microarray data, werein 2005.identified rearrangements These result in the fusion of genes two that Recent clinical trials have demonstrated that immunotherapy-based treatments hold promise for prostate prostate for promise hold treatments immunotherapy-based that have trials demonstrated clinical Recent PCF YOUNGPCF INVESTIGATOR AWARD PCF YOUNG INVESTIGATOR AWARD - ANONYMOUS DONOR Nima Sharifi, MD Sharifi, Nima Providence Portland Medical Center Medical Portland Providence Center W. Research Franz Cancer Robert Institute, Research Chiles A. Earle further enhancefurther cancer vaccine therapy by the discovery and development of new classes of for innovative drugs for the treatment of this disease. Targeting genes is nowspecific possible, but the E FRAK FAMILYFRAK YOUNG -PCF INVESTIGATOR AWARD 13

2008 ProgressProgress Report Report A GLOBAL RESEARCH ENTERPRISE

Countries with Research Sites Funded by the PCF

PCF-DoD Prostate Cancer Clinical Trials Consortium Sites

Many Countries, One Goal

Although based in the U.S., the Prostate Cancer Foundation’s research enterprise has a far-reaching global presence, making it an organization without borders. It has solidified a global commitment to the end of prostate cancer. Receiving a research grant from the PCF has grown to become a prestigious milestone for both researchers and their institutions. Having raised more than $370 million to find a cure, the PCF has funded more than 1,500 projects at nearly 200 institutions in twelve countries: Australia, Austria, Canada, Finland, Germany, Israel, Japan, the Netherlands, Sweden, Switzerland, United Kingdom and the United States.

14 • • • 2008 Challenge2008 Awards • • • 105 instititions in 11 countries 113 applications received from 5 multinational collaborations 9 programs funded with athree- year $21.1 million commitment submitted applications • • 2008 2008 Young Investigator Awards • • 76 applications received from 14 20 investigators funded with a three-year $4.3 million commitment instititions in 8countries • • • 2009 Creativity2009 Awards • • • 10 one-year programs funded with 70 percent of past programs have 341 applications received (Q4 2008) gone on to earn additional funding a $1.0 million commitment from 151 instititions in 15 countries 15

2008 ProgressProgress Report Report A Special Thank you The Prostate Cancer Foundation would like to thank everyone who has supported us over the last sixteen years. We gratefully acknowledge the following individuals, foundations, corporations and others who have given at least $5,000 since our inception.

Founders Lawrence J. Ellison Foundation Richard S. Fuld, Jr. ($50,000,000+) Christian B. Evensen Mark Redmond The David Geffen Foundation Milken Family Foundation Sue Gin Brian and Patricia Reynolds Richard and Phyllis Gelb D. Wayne and Anne Gittinger Leonard and Louise Riggio Genentech Foundation Founder’s Circle Golfers Against Cancer Marc J. and Carolyn Rowan Gen-Probe Incorporated ($2,000,000 - $49,999,999) The Greenspun Family Foundation Gene and Marianne Salmon Eric and Anne Gleacher Anonymous (2) Guggenheim Investment Management, Sanofi-Synthelabo Pamela and Robert B. Goergen LLC Leon and Debra Black The John F. Scarpa Foundation Thomas and Holly Gores Peter Karmanos, Jr. Bristol-Myers Squibb Company Melvin and Bren Simon Charitable Greenbriar Golf Association C. Michael and Elizabeth Kojaian Foundation No.1 The Charles Evans Foundation Orland S. Greene Major League Baseball Charity, Inc. Paul and Elle Stephens Jamie B. Coulter Wayne and Janet Gretzky Richard N. Merkin, MD Sterling Equities David and Julia Koch Martin and Audrey Gruss Joy and Jerry Monkarsh Family Robert & Jane Toll Foundation Thomas H. Lee and Ann Tenenbaum Richard B. Handler Foundation Warren and Jale Trepp Carl Lindner Joseph W. Harch Gordon E. Moore Clyde T. Turner Lowell Milken Thomas O. Hicks Bruce and Jeannie Nordstrom Leslie L. Vadasz Michael and Lori Milken Hilton Hotels Corporation Novartis Pharmaceuticals Corporation Varian Medical Systems, Inc. The News Corporation Foundation Leo Hindery, Jr. Lewis and Peg Ranieri Robert and Angela Voss Stewart and Lynda Resnick Hugo Boss Fashions, Inc. William A. Richardson Dennis and Phyllis Washington Safeway, Inc. Jon and Karen Huntsman Ellen and Richard V. Sandler, Esq. Foundation M. Shanken, Chairman/ M. Shanken Carl and Gail Icahn Sanofi-Aventis Gary and Karen Winnick Communications, Inc. Richard and Deborah Justice Mickey and Karen Shapiro Stephen and Elaine Wynn Mel and Terry Karmazin Lester and Sue Smith Foundation Partners David Karpol Leadership Circle Edward M. Snider ($100,000 - $249,999) Solomon Kerzner ($1,000,000 - $1,999,999) Stuart Subotnick Anonymous (2) Michael and Jena King Tarnopol Family Foundation, Inc. William and Donna Acquavella W. C. Klintworth Anonymous (7) Yahoo! The G. Chris Andersen Family Foundation Knowledge Universe Abbott Laboratories Phillip and Nancy Anschutz The Leeds Family Foundation Aventis Pharmaceuticals, Inc. Patrons Ambassador George L. Argyros, Sr. W. Howard and Mary Lester Baume & Mercier Co. ($250,000 - $499,999) M. Anthony and Anne Fisher Solomon and Rosie Lew Conde Nast Publications, Inc. Brian and Kathleen Bean Arnie’s Army Battles Prostate Cancer Peter B. Lewis Charles F. Dolan Charles and Michelle Becker Atlanta Hawks William and Phyllis Mack William L. Edwards Marc R. Benioff The Lynn Aymar Family Foundation Marin Community Foundation Edward P. Evans Foundation Bloomberg LP Chris and Tory Bagdasarian Leni and Peter May Andrew S. Grove The Eli and Edythe Broad Foundation Charles F. Baird, Jr. Bruce R. and Jolene M. McCaw Fund Kern Family Fund James and Patricia Cayne Robert Baldwin George A. Mealey Sidney Kimmel L. John Doerr Ron and Judy Baron Robert A. Meister Rush Limbaugh Durden Foundation The Cecile and Fred Bartman Foundation Avram Miller The Lincy Foundation David and Marsha Ederer Braman Family Foundation S. Leslie and Barbara Misrock Carol and Earle I. Mack Ralph and Cynthia Finerman Gary S. Broad Kenneth and Julie Moelis Charles N. Mathewson Foundation The Gillette Company The Brookdale Foundation Moore Family Foundation The Craig and Susan McCaw Foundation Howard Gittis John and Barbara Burns John and Rebecca Moores Movember, Inc. Phillip and Lyn Goldstein August A. Busch IV Marc and Jane Nathanson James Newman Harkins Charitable Gift Fund California State Council of Laborers Nativity Jesuit Middle School Kerry Packer Heinz North America Callaway Golf Sales Company Linden Nelson Nelson and Claudia Peltz Steven and Tomisue Hilbert Ely R. Callaway George and Sandra Norcross Ronald O. Perelman The R.D. and Joan Dale Hubbard Wayne Calloway John and Sally Nordstrom PGA Tour Charities, Inc Foundation CAO International, Inc. OSI Pharmaceuticals Julian H. Robertson, Jr. Ray and Ghada Irani Cendant Corporation Palermo Ravich Family Foundation William A. Schwartz Peter W. Janssen John and Jennifer Chalsty Joel M. Pashcow Jane and Terry Semel Michael Jordan Max C. Chapman, Jr. Rick Pitino David E. and Beth Kobliner Shaw Kissick Family Foundation Jerry and Adrianne Cohen Bruce I. Raben Thomas Spiegel Charles G. Koch James H. Coleman Sumner and Paula Redstone Wade F.B. Thompson Charitable Herb and Natalie Kohler Foundation Robert D. Collins Fund Allan V. Rose Robert A. Kotick Ted and Dani Virtue Concern Foundation Lew Rothman Kovler Family Foundation Martin and Pamela Wygod The Carole & Robert Daly Charitable The Rachel and Lewis Rudin Family Lamkin Corporation Foundation Foundation, Inc. Stanley and Barbara Zax Richard S. and Karen LeFrak Charitable Neil P. DeFeo Larry W. Ruvo Benefactors Foundation Ronald M. DeFeo Haim and Cheryl Saban ($500,000 - $999,999) Gary and Tina Lowenthal Thomas and Gun Denhart The San Francisco Foundation Jeffrey A. Marcus James and Kristin Dolan San Francisco Giants Anonymous (3) F. W. McCarthy Foundation Dunwoody Senior Men’s Golf Association Stephen A. Schwarzman Advance Magazine Group Medical Research Agencies of America Jeremy D. Eden Brett T. Setzer Joseph and Annette Allen Richard Mejasich Lee and Daniele Einsidler David and Janelle Shaffer Robert K. Barth MidOcean Partners Don Engel J. Gary and O.J. Shansby Foundation Eric D. Becker Jay and Elaine Moorin, Alain and Iris Ernst & Young LLP Shoes for Crews, LLC The Bunker Foundation Schreiber, and ProQuest Investments Robert S. Evans Silent Partners Inc. Ronald W. Burkle Joseph Neubauer William F. Farley Lisa and Jeffrey Silverman Winston H. Chen, PhD Madeleine and Allen Paulson Sidney E. Frank Skull Creek Development Stephen and Chantal Cloobeck Sandra and Lawrence Post Family Friendship Foundation, Inc. Eric and Susan Smidt

16 Don Soffer William B. Finneran L. Mark Newman Family Foundation Jude T. Barbera, MD David M. Solomon First Data Western Union Foundation and Phil R. North David W. Bash, PhD and Judy Oliver-Bash, Martin & Toni Sosnoff Foundation The Safeway Foundation Ruth Ornest PhD Alex G. Spanos David and Judith Fleischer Jon Otto Candice Beaumont The John R. & Inge P. Stafford Foundation Paul M. Fleming The Palin Family Foundation, Inc. Robert A. Belfer Joe Fred Starr Forester Family Foundation Jim Pattison Art H. Bilger Avy and Marcie Stein Theodore J. Forstmann Ethan Penner Les and Sheri Biller Joseph and Diane Steinberg 1992 Freeport-McMoRan Foundation The Picower Foundation Bobby Blair Charitable Trust Michael Frey Chris Prezioso Charles X. Block Ernest E. Stempel Carlos Fuente, Jr. Pritzker Foundation Bluefish Concierge, Inc. The Stern Family Foundation The Gaba Family Foundation Alan Quasha Salvatore and Alison Bommarito Roger and Susan Stone Arthur J. Gallagher & Co. Martin and Patricia Raynes Bonita Bay Community Swing for the Cure Gantcher Family Philanthropic Fund The Republic of Tea David Booth Marty Tenenbaum Jeffrey D. Garguilo and Valerie Boyd Tony Ressler and Jamie Gertz Tony Borhani Laurence and Billie Tisch Arthur and Linda Gelb Richard S. Ressler Boston Red Sox Foundation Report Progress 2008 Tom and Diane Tuft Jay Geldmacher Meshulam Riklis Denis A. Bovin Barbara Tyson Global Fitness Holdings, LLC The Riordan Foundation The Braka Philanthropic Foundation Van Van Auken Henry and Arline Gluck George R. Roberts Harry M. Brittenham, Esq. The Wagner Family Foundation Stanley P. Gold The Rose Foundation Coco Brown Ira Walker Jeremy P. Goldberg Andrew M. Rosenfield Thomas and Jo Anne Bruno Raul and Vicki Walters Richard and Marcia Goldberg Pat and E. John Rosenwald John M. Bryan Wasserman, Comden, Casselman & John R. and Kiendl Dauphinot Gordon Steven and Daryl Roth Brian P. Burns Pearson, LLP Fund Eric Rothfeld Arthur Byrnes Will Weinstein John and Kathleen Gorman Peter H. Rothschild Dick and Lisa Cashin Thomas and Emily Weisel GPC Biotech Mike Ryan Andrew S. Clare John F. Welch, Jr. William and Susan Gross Ronald Salkow Brian and Denise Cobb Dr. Herbert A. Wertheim The Sam and Sarah Grossinger The Mara and Ricky Sandler Foundation Gregory and Monica Coleman Jim and Kim Williams Foundation Richard J. Schmeelk David and Courtney Corleto Sam Zell Allen Grubman Allen B. Schwartz Country Club of Roswell Selig Zises Norb Guziewicz Thomas J. Shannon, Jr. Lester and Renee Crown J. Ira and Nicki Harris Mace and Jan Siegel Edgar and Elissa Cullman Associates Alan and Vivien Hassenfeld Harvey L. Silbert, Esq. Ian M. Cumming ($50,000 - $99,999) Houston Golf Association Jeffrey and Helaine Silverstein Cytogen Corporation Anonymous (5) Roy W. Howard Herb Simon Davidoff of Geneva Robert W. Adler James Hudson William E. and Tonia Donnelley Simon Robert and Kelly Day AJA Charitable Fund Michael Huffington Paul and Celia Sirotkin Celine Dion Foundation Robert and Jodi Allardice Internet Real Estate Group, LLC Stuart M. Sloan Mark Donnelly Edward C. Allred Jim Beam Brands Co. Jeff P. Smith Michael Dougherty Altadis USA, Inc. Joseph H. Kanter Foundation The Snider Foundation Joseph Drown Foundation Anaheim Angels Matthew Kaplan Southern California District Council of Efficiency Enterprises Eric J. Aronson Bruce E. Karatz Laborers Harvey P. Eisen Michael and Marlene Aufrecht John Kelley Saul P. Steinberg Lewis M. Eisenberg Facundo L. Bacardi Melvyn N. Klein James Stern Lawrence R. Elins Mr. and Mrs. Robert Baker Family David and Janet Kline Fund Sternlicht Family Foundation Mary and David Emerson Foundation The Kobrand Foundation Louis B. Susman The Entertainment Industry Foundation Roger Barnett Fred Kolber Allan Tessler Thomas J. Fazio Kathy and Frank Baxter Timothy Koogle William H. Tilley Ferolito, Vultaggio & Sons Erin and Douglas Becker Dewanto Kurniawan Time Inc. Cary Fields Samuel Belzberg Laborers’ International Union of North Pier Luigi Tolaini Steve Fink Marshall Bennett America Joe and Alice Torre Alex Fisher Ken Berg Emeril Lagasse Jeanette Trepp Peter E. Fleming, Jr. Phyllis and Martin Berman Benjamin V. and Linda Lambert Trimaran Capital Partners Todd Follmer Robert and Catherine Beyer Kenneth and Linda Lay Vadasz Family Foundation Theo and Constance Folz Frank and Carol Biondi, Jr. Lehman Brothers, Inc. Clark Van Nostrand Lionel Frais BlackRock Financial Management Robert Levin Charles J. Wagner John R. Frank Jim & Diane Blair Charitable Foundation Robert E. Linton Mr. and Mrs. Jay L. Wallberg Keith Frankel Dan Blumenthal Ira A. Lipman Alice Walton Jim Freer Boston Red Sox Los Angeles Lakers Cheng Ching Wang Robert Fremont Jerry Brassfield Laurence and Karen Mandelbaum Casey and Laura Wasserman Jerry Friedman Shann Brassfield Bernard Marcus Jerry and Jane Weintraub Josh S. Friedman Gresham T. Brebach, Jr. Michael Marek Gary and Nina Wexler Steven Friedman Steven A. Burd Margaritaville Holdings, LLC Gregory White Paul R. Garcia Frank Caufield Joseph and Anne McCann David Yandry Philip H. Geier, Jr. Ray and Patti Chambers John E. McCaw Don Yannias Stephen and Mindy Geppi Alfred and Kathryn Checchi Richard McKenzie, Jr. Zapolin Transactional Ventures, Inc. Russell Geyser Chicago White Sox Jerome Meislin Charles and Vivian Gillespie Marshall and Maureen Cogan Barry Meyer Friends The Honorable Rudolph W. Giuliani Robert and Beverly Cohen Family Millennium Pharmaceuticals, Inc. ($25,000 - $49,999) Givingcapital, LLC Foundation Michael Minikes Anonymous (1) GNC Countrywide Credit Industries Edward J. Minskoff Don Ackerman Goldentree Asset Management Howard Cox Morongo Band of Mission Indians Nat. Neale M. Albert, Esq. Bruce Goldstein Credit Suisse First Boston Corporation Amer. Right Fund Norman E. Alexander Eric Goldstein Dendreon Corporation Robert E. Morrow Allchin Foundation Michael Goldstein Detroit Tigers Movado Group, Inc. Arby’s Litto Gomez Michael D. Dingman Angelo and Phyllis Mozilo Frank J. Arcella Bennett and Meg Goodman Ty and Fran Durekas Ken Nees Matthew Arcella Cheryl and Edward Gordon Robert and Tricia Earl Neiman Marcus Direct Roland E. Arnall Maureen V. Gorman Bruce Eichner Netjets Aviation, Inc. Ashton Distributors, Inc. Alan C. Greenberg David J. Epstein Aviv Nevo AstraZeneca John A. Griffin Faith, Love, Hope, Win Foundation New York Mets Foundation, Inc. Robert Bales Mr. and Mrs. Kenneth B. Hamlet

17 Clay W. Hamlin, III Prostate Cancer Foundation of Greenbriar Dan Baldwin Jimmy and Patti Connors John J. Hannan Royce G. Pulliam Martin and Dorothy Bandier Nancy and James Cook Reed and Nan Harman Mark Quigley Jeffrey C. and Lori Barbakow The David and Sheila Cornstein William Hartnett Ed W. Rabin Sol Barer Foundation Ralph and Kay Hemingway Richard E. Rainwater F. Harlan Batrus Corte Bella Women’s Golf Association Sam Herzberg Ramblewood Country Club Michael J. Batza, Jr. Jack B. Corwin John and Susan Hess Bob Roberts William P. Beatson, Jr. Ken Cory Samuel J. Heyman Bill R. Roberts Richard I. Beattie Robert H. Cosgriff Kenneth and Janet Himmel Richard and Barbara Rosenberg Warren Beatty Terry Cosgrove HLT Prostate Cancer Fund Stan and Patti Rosenfeld Michel De Beaumont The Gerald and Daphna Cramer Family Diane and H. S. Hoffman Round Hill Country Club Dr. Gary S. Becker Foundation Charlie J. Horky Andrew Ruotolo Michael Becker Alberto Cribiore David S. Howe and Charlene Wang Barry L. Rupp Mitch Becker Robert and Mary Ann Cross Michael R. Howland Alvin and Marilyn Rush Allen J. Beeber Cuba Club Charles and Barbara Hurwitz Peter M. Sacerdote Foundation William J. Bell Chip Cushman The Iacocca Foundation Ronald S. Saks Lee and Susan Benton Theodore Cutler Vincent Iorio David Sambol Eric L. Berg Dabney/Resnick Imperial IRI Golf Management, LP Richard and Margaret Santulli Jeff Berg Dalio Family Foundation, Inc. Jack and Ginger, LLC John H. Schnatter Anthony Bergamo, Esq. John Daly Jacks Broken Open Irving Schneider Elliott H. Berger Darling Family Fund Steve and Ellen Jackson Michael and Paola Schulhof Daniel G. Bergstein J. Morton Davis Stanley R. Jaffe David and Fela Shapell David Berkoski Marvin and Barbara Davis John Kahrhoff Memorial Golf William Shaw The Judy and Howard Berkowitz Roger J. Davis Gerald Katell Howard P. Shore Foundation Joseph J. Dempsey The Fritz and Adelaide Kauffman David and Lynn Silfen Allen J. Bernstein Cosmo DeNicola Foundation, Inc. Mark J. Simon Fred B. Bialek Donald J. Deutsch Stephen and Marina Kaufman Fred L. Smith The Black Family Charitable Foundation, Deutsche Bank KB Home Smithburg Family Foundation Inc. Terry and Marilyn Diamond J. Christopher Kennedy Irwin and Lorri Spiegel The Stanley & Joyce Black Family Dietz & Watson Foundation Michael Klein St. Louis Cardinals Foundation Richard DiMeola Henry R. Kravis Fred and Sharon Stein Joni Hirsch Blackman Dinan Family Foundation Bill Lane, Jr. Steinberg Family Fund, Inc. Harvey Blau Donaldson, Lufkin & Jenrette Jeffrey & Nancy Lane Foundation, Inc. Spencer Stokes Dennis Block Carl Doumani Gerrity Lansing Stricklin Account of Fidelity Charitable Bloomberg Financial Markets Co. Dow Electronics Bennett and Jerri Lebow Gift Fund Bernt O. Bodal Milton H. Dresner Foundation, Inc. Ken Leese Burt and Mary Sugarman Burton Borman David H. Dreyfuss Steve Lehman Jim Tarlton Albert R. Boscov Dunwoody Country Club John S. Levy Douglas P. Teitelbaum G. Michael Boswell Joseph J. Dvorak, Jr. Linder Charitable Remainder Unitrust William Thompson Reggie Bowerman Alvin Dworman Joseph Rob Link James Tisch Steve Braverman Eastdil Realty, Inc. Lord’s Valley Country Club Bruce E. and Robbi S. Toll Foundation Bernard and Judy Briskin Charles Edelstein Los Angeles Dodgers Marc and Mindy Utay Broad Street Productions Stephen Einhorn Joe Lumarda Peter Vegso Brooklyn Hospital Center Steve Eiseman Susan E. Lynch Michael and Laura Venerable Harry J. Brown Foundation David F. Eisner Gene E. Lynn Linda J. Wachner Gloria S. Browning Niko Elmaleh Donald and Hilda Lytton Samuel Waksal John M. Bryan Family Fund Roger A. Enrico David S. Mack Arthur Becker and Vera Wang Bryanston Group, Inc. Mike Ensign Fredric Mack Elmer Ward Bulk Truck and Transport Service, Inc. The Daniel J. Epstein Fund of the Jewish Harvey Mackay Michael and Jill Weinstein Kurt W. Butenhoff Community Foundation Howard and Nancy Marks Stephen and Phyllis West Bernie F. Butler Jeff Epstein Stanley and Pamela Maron Henry Wilf Michael Butler Evergreen Foundation Robert and Joan Masterson Christopher and Kristine Williams The Capital Group Companies Charitable Jonathan D. Farkas Harold Matzner Alexander J. Witherill Foundation Federated Department Stores Marilyn and Robert May Douglas Wood Cardean Learning Foundation Keith W. McCaw Rick Wooley Cardinals Care Brad Felenstein Michael McKeever Don Zacharia Michael Caridi Robert M. Fell Dennis Mehiel Liam Carlos James and Alise Ferency Merck and Co., Inc. Supporters Johnny Carson Mike Ferry Herman and Susan Merinoff ($10,000 - $24,999) Donald and Nancy Carter The Diane and Elliot Feuerstein Fund of Harold M. Messmer, Jr. Anonymous (1) Edwin P. Carter the Jewish Community Foundation Theodore N. Miller David and Kay Aaker Marx L. Cazenave, II Gregory F. Kiernan Minnesota Twins Paul Abecassis Tom Celani Mark Finerman Molecular Insight Pharmaceuticals, Inc. S. Daniel Abraham Cell Genesys, Inc. Gerald B. Finneran Jim Mooney Abramson Family Foundation, Inc. Centocor, Inc. Jerome and Anne Fisher James F. Moore Joseph P. Adams, Jr. Irwin Chafetz Larry and Kathleen Fisher Mark E. Mortimer Sheldon Adelson Charity Folks, Inc. Lester and Gwen Fisher Stuart W. Moselman Larry Alleto Linda Chen Richard Fisher John Nickoll Bruce and Elvin Ambler Peter Chernin Dawn N. Fitzpatrick T. D. O’Connell Lee W. Ang Allen and Jill Chozen Joseph Flom Chris K. Olander Judd Apatow Chubb Federal Insurance Company Florida Marlins Pierre and Pam Omidyar Michael F. Armstrong Citigroup Steven T. Florio Dean E. Palin Michael F. Ashby Clarion Operating , LLC Lynn Forester Larry R. Palmer, CEP, CTP Robert Atherton The Clark Charitable Foundation Michael G. Foster, Jr. William J. Polvino, MD Atlanta Braves Foundation, Inc. H. Lawrence Clark William C. Foster John and Laura Pomerantz Mark and Debbie Attanasio The Clinton Family Foundation Foxsports.com Portland Bolt & Manufacturing Jerry Auerbach Coca-Cola Co. Fred C. Hutchinson Cancer Research Center Steve Posner Autism Speaks, Inc. Harold K. Cohen Paul Fribourg Post Advisory Group Abraham Azoulay Mitchell H. Cohen Friedman Family Foundation Anthony & Jeanne Pritzker Family Baby Togs Jim and Marcia Colbert Larry H. Friend Foundation Bacon, LLC Commerce Bank, North, N.A.

18 Peter Fudge Leonard R. Jaskol Stephen J. Marcus Maury Povich and Connie Chung Jeffrey Furman The JCT Foundation Mariners Care Michael J. Price Frederick and Peggy Furth Christopher M. Jeffries Howard and Stacy Marks William L. Price Ronald H. Galowich Michael and Linda Jesselson Nancy Marks Wayne Prim, Jr. Brian Gamache Clark A. Johnson Marvin Engineering Co., Inc. Jay Pritzker Michael and Lynn Garvey Johnson Bank Maverick Capital Foundation Prometheus International, Inc. Arie Genger Allen N. Jones Kenneth Mazik Quiksilver Foundation Guilford and Diane Glazer Ellis B. Jones Larry Mazzola Harvey and Pauline Radler Alan and Marlene Gleicher Glenn R. Jones Michael and Kristy McChesney Sheri and Marc Rapaport Fund of the Seth Glickenhaus The Joseph and Ida Foundation Inc. Les G. McCraw, Jr. Jewish Community Foundation Colin Goddard, PhD Mitch Julis Ashley and Jeffrey McDermott Mr. and Mrs. Joseph Rascoff Bradley and Sunny Goldberg David G. Kabiller, CFA John and Constance McGillicuddy Bruce Ratner Michael A. Goldberg The Kandell Fund MCI WorldCom Foundation Michael Ratner R&M Goldberg Family Foundation Kansas City Royals Thomas J. McKearn Randolph and Lindsey Read Andy Goldfarb Harold Sanford Kant, Esq. Miss Kara McKinley John S. Reed Report Progress 2008 R. Anthony Goldman Abraham Kaplan Foundation J. P. McManus Richard and Marget Reneberg Russell D. Goldsmith Donna Karan James A. McRae W. Brent and Brenda Rice The Golfworks Scott G. Kasen Medco Containment Co Denise Rich The Gordon Family Foundation Peter M. Kash Keith Meister Robin Richards Edward and Cheryl Gordon Howard and Susan Kaskel Todd Meister James S. Riepe Family Foundation Berry Gordy, Jr. David and Silvana Kay Prakash Melwani Richard A. Rigg Abraham D. Gosman Joshua and Joia Kazam Arnon Milchan Harold W. Ripps Fredric Gould Dean C. Kehler Lee and Sylvie Millstein Richard K. Robbins John P. Gould Brian King Milwaukee Brewers Brian L. Roberts Laurence Graff Don King Productions, Inc. Larry A. Mizel Kenn Roberts Mark Grant Michael G. King, Jr. Robert Michael Mondavi Ralph J. Roberts Madison and Susan Graves Lila Kingsley Charles K. Monfort Thomas and Mary Alice Roberts George D. Grayson Kirkland & Ellis Foundation Eugene Monkarsh James D. Robinson, III George & Reva Graziadio Foundation Joel Kirschbaum David Moore Rodney Strong Vineyards Steven and Dorothea Green Daniel J. Kleiman Jacques J. Moore Gerald Ronson Gary and Sandra Grimes Calvin Klein Pete Moore Allison Rosen Grizzard Family Foundation, Inc James W. Klein Jerry Moss Fredric D. Rosen Julie Groshens John Kliger Wayne Mueller Paul and Catherine Rosenberger Michael S. Gross Michael and Patricia Klowden Donald R. Mullen Betsy Ross Haarlow Family Charitable Foundation KML Golf, LLC Peter Mullin Byron Roth Blair Haarlow Harold and Shirley Kobliner Bill Mundell James Rothstein Roger S. Haber Jeff Koffman Hilary Musser Michel Roux Kerry and Kelly Hagen Roger and Lorraine Kotch Miles Nadal Michael D. Rudd David and Leslie Hahn KPMG, LLC Naples Drive for the Cure James Russell Brian L. Halla Jules B. Kroll The Nash Family Foundation Kenneth and Dina Russell James A. Harmon A. B. Krongard Menasche M. Nass Edward B. Rust, Jr. Richard J. Harrington Mark Kurland David Nazarian Stephen Ruzow Mel Harris Herbert and Edyth Kurz NBS Diamonds, Inc. Steve Sanak William B. Harrison, Jr. Lachman Family Foundation Marty Nealon Raymond and Helen Sandler Richard C. Hartnack L’Acquisition Corporation Rooney Nelson Richard Sandor Albert and Irene Hartog Kenneth G. Langone New England Financial Michael Sandorffy Richard J. Heckmann Leonard and Evelyn Lauder New Jersey Basketball, LLC Sylvan Schefler H.J. Heinz Company William P. Lauder Wayne and Kathleen Newton Andrew Scheinman Andrew L. Heiskell Steve Lawrence and Eydie Gorme NFL Charities David Schneider Bruce Heller Norman Lear Dr. Perry Nisen, MD, PhD Raymond D. Schoenbaum Jane Heller Lederman Family Foundation Northern California District Council of Lewis M. Schott Jerry Hennessy Don and Rita Lee Laborers Ian Schrager Lawrence Herbert Stephen R. Leibowitz Karen van Nouhuys David K. Schulhof Norma and Leon Hess Norma and Alfred Lerner Novacea, Inc. Schultz Family Foundation Andrew R. Heyer Julius and Miriam Lesner Marlene Nusbaum Marvin H. Schur Highlands United Methodist Men Frederick N. Levinger Oakland Athletics Charles and Helen Schwab Rick Hill Frances and Jack Levy Foundation Cindy K. Olson Alan D. Schwartz Douglas Hirsch and Holly Ander Richard Levy Peter Busch Orthwein Barry K. Schwartz Family Foundation The Armin & Esther Hirsch Foundation Loida N. Lewis Ozaukee Country Club Schwartz, Kales Accountancy Corp. Hitching Post Motels Robert Lienau Gregory J. and Mary V. Pacelli Ted Schwartz Beth Hollfelder Lights Out for Cancer Chuck Palombini Charles Scott Butch Holmes Mrs. Arthur Liman Marvin Parsons Russell Scott, Jr. Jane Holzer Steven Lipman Alan Patricof Tony Scotti Homayoun Homampour Michael D. London Norman J. Pattiz Sebastiani Vineyards, Inc. Home Box Office Lord, Abbett & Co., LLC Paul, Weiss, Rifkind, Wharton & Garrison, Security Life Inc. Group Steven and Cathy Hooper David B. Lowry LLP Henry Seiden Houston Astros Rufus and Patricia Lumry David Pecker Ivan G. Seidenberg D. E. Brice Howe Robert G. Lusk Gerry Pencer Martin Selig Helmut Huber LZR Sports, LLC Arthur Penn Mike Shad Gene Humphrey Jerome D. Mack Pensions 2000 Michael Shapiro Michael Hyatt Richard Mack Leonard C. Perham Shearman & Sterling Royce Imhoff Macquarie Bank Limited Phillips-Van Heusen Foundation, Inc. Howard Shecter International Financiers, Inc. Macy’s Phoenix Home Life Mutual Insurance Mark Shenkman Invemed Associates, LLC John Magliocco Company Robert D. Shipp Ironman Motivations Peter A. Magowan Elizabeth Pinsonault Boaz Shonfeld Herb W. Jacobs Mandalay Resort Group Albert and Jeanine Pirro Walter Shorenstein Nathan P. Jacobs Alan and Barbara Mandelbaum Michael A. Pitino Stan Shuster Sheldon Jacobs Mandelbaum Foundation Mack Pogue Stanley J. Sidel Ron Jacoby Stuart Manheim, CPA Carl and Eloise Pohlad Family Foundation Sanford C. Sigoloff Robert M. Jaffe Mel Mannion The Poses Family Foundation Eugene Silverman

19 Jay B Silverman Fred Wolf Tim Blixseth Marion J. Davis, Jr. Thomas M. Simms Douglas J. Wood James A. Block Peter and Julie Dawson Ted Simpkins C. Tal Wooten, Jr. Ron Boeddeker Ed DeBartolo, Jr. Sanford Sirulnick Leah Wurzberger Franklin Otis Booth, Jr. Delaware North Companies, Inc. John and Cindy Sites Young Presidents Organization Los Kurt T. Borowsky Delcal Enterprises, Inc. Charles B. Slack Angeles Chapter Richard Boughner Dodger Dream Foundation, Inc. Alan B. Slifka Gerard Yvernault Boustead Family Foundation, Inc. Robert Dodson Lynn Smiledge Louis G. Zachary, Jr. Larry Bowman J. Douglas and Marian Pardee John F. Smith, Jr. Harriet Zaretsky Thomas S. Bowman Drexel University Matthew and Tracy Smith Jeffrey Dunston Zients Leonard Boxer William E. Dreyer Orin Smith Roy Zuckerberg Thomas Breitling Daniel A. Duc Snyder Weiner Weltchek & Vogelstein Robert A. Zummo Stephen M. Brett Duch Family Fund of the Community Marilyn Sobel Sergio Zyman Pete Briger Foundation of New Jersey Sirens Society Pam Brill Raymond Duncan Bruce Sokoloff Contributors Nancy Brinker Eagle Watch Ladies Golf Association Bob Solomon ($5,000 - $9,999) Gary Briskman J. C. Earle Family Fund Warren J. Spector Anonymous (1) F. James Brock Walter Eberstadt Allison Speer 12th Man Foundation Edward Brodsky Spencer F. Eccles Aaron and Candy Spelling Robert J. Abt Jeffrey P. Brown David B. Edelson Jerry Speyer The Adler Family Foundation, Inc. Richard A. Brown Daniel D. Ederer Lawrence Spira, MD Advance Shared Services Center Sam Brown Maurits E. Edersheim Sports Licensed Division of the Adidas AIECA of America, Inc. Christopher H. Browne Anders B. Eklov Group, LLC AIM Management Group Richard C. Browne Richard and Gail Elden Sportsgrants, Inc. Alvin R. Albe, Jr. C. Kenneth Brumit Elmwood Country Club The Starr Foundation Ellis J. Alden Marc R. Brutten Mr. and Mrs. Alfred Engelberg Joseph Stein Richard L. Alderson Deborah L. Burger, Inc. Robert Englander Jeffrey Steiner R. Jack and Beulah Alexander Alan A. Burgess Yan Erlikh Irving Stenn, Jr. Donald and June Alford William and Elizabeth Burroughs Aaron R. Eshman Karl Sternbaum Allied Beverage Group, LLC Jack Burstein Linda Evangelista Gary Stoneburner Arthur G. Altschul, Jr. Richard Byrd Peter Evans Michael Strauss Ellsworth C. Alvord, III Roger and Mary Campbell William F. Evans Lawrence Sheldon Stroll Richard W. Alvord Cancer Awareness Gold at Heritage Eagle Eugene and Sallyann Fama Melanie Sturm American Endowment Foundation Bend Samer Farah, MD Marianne Sufrin Ameripoint Foundation Phil Caputo Andrew Farkas Sanford and Charna Sugar John Angelo James A. Cardelli John Farnsworth Sunbelt Beverage Company, LLC Tom Armstrong CARE Michael S. Fawer Katharyn Swintek Arris Interactive LLC Ronald G. Carley Dr. Jeffrey P. Feingold Tag Associates, LLC Phillip Asherian William M. Carson Stanley M. Feingold Roberta R. Tanenbaum Michael Ashkin Frank L. Cassidy, Jr. Irving Feintech Jeremiah and Nonie Tarr Sherrell Aston Matthew J. Celozzi II, PhD Jerry Della Femina Stanley G. Tate Victor K. Atkins Chajet Family Foundation Frank and Victoria Fertitta Fredricka Taubitz Elisangela and David Aufrecht Michael J. Charles David Fillmore Ian Ross Taylor Susan and Ralph H. August Charlesworth Family Limited Partner Gregory Fischbach Robert Taylor Margaret and Edward Augustine Gary Charlesworth Richard B. Fisher Anthony Terlato Aureon Laboratories, Inc. Sophie Chen, PhD Stephen B. Fiverson Charles and Adele Thurnher Rick G. Avare Bernd Chorengel Dennis Flatt Andrew H. and Ann Tisch Bacardi Limited Clarium Capital Management, LLC Jean Fogelberg Daniel and Bonnie Tisch Roland and Beverly Bacci Greg Clark Robert Forbes Steven H. Tishman David and Michelle Bach John H. Claster Sam Forman Dennis A. Tito Baltimore Orioles Cleveland Cavaliers Gayle Devers Fortune John T. Toland Jeffrey and Pamela Balton Steven Clinton David Foster Richard P. Torykian, Sr. The Bandier Family Foundation CMA Consulting Services Michael F. Frankel Jesse I. Treu Scott P. Barasch Bert Cohen Franklin Country Club Prabhakar Tripuraneni, MD, FACR Norma and Paul Barash Joseph M. Cohen Albert Fried, Jr. The Trump Organization Alexander E. Barkas and Lynda Wijcik Karen B. Cohen Foundation Inc Joel Friedland Tudor Investment Corporation Janice Barney Richard D. Cohen Robert and Ann Fromer Robb & Elizabeth Tyler Foundation, Inc. John R. Barney The Betsy and Alan Cohn Foundation, Inc. Front Line Management Group, Inc. Valquip Corporation The Barrack Foundation Victor A. Cohn Roy Furman The C. George Van Kampen Foundation Tyler Barth Mary and Robert Colgan Tom W. Gamel Varhegyi Foundation Charles T. Bauer Collington Transportation Golf Outing Howard L. and Judie Ganek Philanthropic Mary T. Venable Ted Baum William S. Comanor, PhD Fund The Vons Companies Charitable The Baupost Group, LLC Kerby and Judith Confer Lloyd Garver Foundation, Inc. David I. Bavar Connecticut MSBL Frank Gehry Rosemary Vrablic Lee Beattie Michelle A. Connelly Alan Gelband Don Vultaggio Jack M. Beaven James C. Cook Gelfand, Rennert & Feldman, LLP Shirlene A. Wainer Alan T. Beimfohr Elaine Terner Cooper Georgetown Tobacco & Pipe Stores, Inc. William and Claudia Walters Bradley Bell John Cooper, Jr. S. William Gersten Kenneth Wang John Bendheim Stephen A. Cooper, DMD, PhD Michael F. Gilligan, Jr. William and Sharon Ward Walt L. Bent Peter Coors Tom Giovanelli Latham & Watkins Philip J. Bergan The Copses Family Foundation David H. Glaser Tom Watkins Martin S. Berger Fred Corrado Arthur M. Goldberg Scott Watt Stephen Berger Cotton Creek Men’s Golf Association, Inc. Howard Goldenson Armond Waxman Richard Berkowitz Marshall B. Coyne Steve A. Goldfarb Robert F. Weis Leonard H. Bernheim, Jr. Cresa Partners Dr. Kenneth N. Goldman Melvyn I. Weiss Anthony J. Bettencourt Cullasaja Club, Inc. The Golush Family Charitable Fund of the Morris Weissman William C. Bevins Gregory Cuneo Vanguard Charitable Endowment Whittemore Family Foundation Les Bider Cunningham Security Systems Program Ralph and Wendy Whitworth Marc Blackman Cushman & Wakefield Renee and David Golush Arthur Wiener Robert S. Blank Lucio Dallla and Marta Gasperina Jan Goodman Andrew Wise Michael and Nina Blechman Billy Davis, Jr. Bradford S. Goodwin

20 Richard Goodwin Stanley Katz Kim Martindale Elsie Pecorin, DBA Todd Goodwin Stephen Katz Elliott Masie David R. Pedowitz Jerome S. Gore George Kaufman Norman and Joanne Matthews Robert F. Pence Louis and Nancy Grasmick Ivan Kaufman Giacomo Mattoli James C. Pendergast Jim Grau Ronald S. Kaufman Caryn Mautner Pennsylvania Breast Cancer Coalition Robert Gray Ilan and Linda Kaufthal Thomas and Musa Mayer Mark Perlbinder Barbara and Jerry Greenbaum Richard and Suzanne Kayne James N. McCoy Foundation Charles Persico Charles H. Greenberg Gershon Kekst Richard E. McCready Foundation Fund of James L. Peters Mark Greenhill Donald H. Keltner the Baltimore Community Foundation Robert E. Petersen Robert W. Greenman, Jr. Ken Roberts Company Liam E. McGee Pharmaceutical Research and The Marion and Louis Grossman Keys Foundation John S. McIlwain Manufacturers of America Foundation Kidz, LLC Laureston and Barbara McLellan Phillies Charities, Inc. Robert Grossman Jerry King Don McNamara Cynthia H. Polsky GSI Commerce Kathleen and Kirk Knous Robert J. McNulty Gerald Porter Howard R. Gurvitch Burton Koffman Cynthia and Bryan McWeeney Timothy N. Poster Report Progress 2008 Lynn M. Haff Eugene Kohn Rolf Meijer-Werner Rick Powell Thomas R. Hagadone and Pam Miller Oswaldo Kosta The Melville Foundation Ed Prager John Hagestad Robert Kraft Merrill Lynch & Co. Foundation, Inc. Arlen I. Prentice Hall Dickler Kent Goldstein & Wood, LLP Norman D. Kurtz Leroy Merritt Wayne Prim, Sr. The Hallman Foundation John and Kay Kyle The Morris and Helen Messing Edward Probyn Jesse Halperin Laborers’ International Union of El Foundation Bob Pryt Fred Hameetman Monte-Local 1082 Dwayne Middleton John A. Ptak Mark S. Handler Laborers’ International Union of N. David A. Miller Melody and William Purdy Mark S. Hanson America-Local 300 Laura and Michael Miller Kjell H. Qvale Martin Aaron Harmon Laborers’ International Union-Local 270 Honorable Robert Joseph Miller Mark Rachesky Gilbert W. Harrison LA-CO Industries, Inc. Mary Sullivan and Sherman Miller, IV Robert E. Racicot Lauren M. Hartman Constance C. and Linwood A. Lacy, Jr. Thomas K. Miller Raley’s Gold Rush Classic Edward J. Hawie Foundation Peter H. Mills Max Ramberg Marilyn and Jerry Hayden Fred S. Lafer Phillip S. Mittelman Scott Gregg Rechler Kenneth and Kathryn Henderson Robert F. Lampe, Jr. MLB.com Donald Rechler Thomas S. Henderson and Sally S. Sprenger Lang Foundation Alan Mnuchin Joseph P. Riccardo Henderson Foundation Ira N. Langsan & Lillian Langsan Arthur and Patricia Modell Blair & Kristin Richardson Foundation Arthur Hershaft Philanthropic Fund James J. Moglia Ritz-Carlton Michael B. Hershey Robert Larner, MD David Moore Ritz-Carlton Boston Edward and Gaye Hewson Martin and Sheila Lasky Raymond Moore Lee P. Rizzuto The Annette Heyman Foundation Inc. Ronald Lauder Morongo Band of Mission Indians Karen and W. Scott Robertson David Hicks Lynn M. Leany William S. Morris, III Linda G. Robinson Steven Higger Frank Leanza Morton’s Restaurant Group Sam Robson The Hill Family Charitable Foundation Charles E. Leonard, III Judy Bardugo and Harve H. Mossawir, Jr. Iber Rodriguez Roderick Hills Steve Leonard Paul Motenko Sig Rogich Leslie Wohlhan Himmel Warner LeRoy Charles H. Mott Jeffrey Rosenthal Peter A. Hochfelder Margaret Lesher Joseph M. Murphy Beth and Peter Rosenthal Memorial Fund, Robert W. Hoke John and Betty Levin Alan C. Myers Inc. Richard Scott Hollander Neil Levine Douglas P. Nation Stephen M. Ross Mark Holowesko Dan and Stacey Levitan NBA Properties, Inc. Paul R. Del Rossi Vincent Horcasitas David Levy Renato Negrin Gordon Roth Gerald Horowitz Laurence R. Levy Lee S. Neibart Edward F. Rover John and Sandra Horvitz Edward Lewis Craig T. Nelson Richard and Amy Ruben Thomas J. Howa The Liberal Do-Gooder Foundation Mary-Rose Nelson Howard Rubin Joe Howe David Liebowitz Nestle Waters North America, Inc. Mariano A. Rubino HSK Funding Sio Lindner Blake Lee Neubauer, PhD Cheryl and Stephen Rush Harry and Elsie Huber Samuel S. Lionel Shilom Neuman Denny Ryerson Mark Hughes Jeffrey and Susan Liss Chuck Nicolette, MD Thomas L. Safran Wayne Huizenga The Litwin Foundation, Inc. Niebaum-Coppola Estate Winery Max and Janet Salter James Husband The Loa Productions, Inc. James B. Nish Allan C. Sanders George Hutchinson The Arthur Loeb Foundation Robert Noelke Theodore and Alison Sands Lee Iacocca John L. Loeb, Jr. Douglas and Nancy Norberg Sandy Spring Bank Arthur I. Indursky Shumer Lonoff Greg Norman Jill and Ronald Sargent Institute for Health & Productivity Bob Lorsch Maryann and John Norris Patrick Savin Management Douglas and Nancy Lowe NorthAtlanta National Bank Saybrook Tax-Exempt Advisors, LLC Hale S. Irwin Neil G. Van Luven Nsuh Foundation Randall H. Scarlett The J.P. Morgan Chase Foundation Lyncar Enterprises, Inc. Obermeyer Asset Management Company Anthony Scavo, Jr. Jeremy Jacobs Gordon Maahs James T. O’Brien Al Scheid Max Javit Harry Macklowe The October Foundation for Kids Schmertz Company, Inc Gordon W. Jenkins John Magnier Morris Offit Alfons J. Schmitt Charles Jennings Anthony J. Magro John O’Hurley David M. Schoenthal Jerry Lee, Newton Running Company Brian A. Maki Marvin Olshan Marvin I. Schotland Daryl L. Jesperson Idelisse Malave Shepard Osherow The Lewis Schott Foundation Jewish Federation of Greater Phoenix Judd Malkin Dan Otter Robert Schulman JFD / MJD Golf Open Shareef Malnik San Diego Padres Gerald M. Schuster James and Lorene Jimmerson George J. Maloof Donald P. Pakosh Homer R. Schwartz Alastair J. Johnston Lynette and Praveen Mandal Norm Pappas Governor Arnold Schwarzenegger and Wayne D. Jorgenson Susan Mandelbaum Donald J. Parmet Mrs. Maria Shriver Jay Kaiser Manowitz and Drillings Family Partners Marketing Group Lisa White Schweitzer Kaiser Permanente Foundation Rafael Pastor Peter W. Schweitzer Peter S. Kalikow Marcia and Philip Marcus Thomas J. Patrician Spencer and Jacqueline Segura Thomas J. Kalinske Bernard A. Marden E.H. Patterson Dr. Michael E. Seiff Bruce and Jeanie Kaminsky Mark Asset Management Corporation Frances B. Paulsen Richard M. Seigel Walter Karabian Morris Mark Randall Eric Paulson David M. Shaffer Eric P. Karros Ken Martin Clay Pecorin Michael S. Shannon

21 Carl and Ruth Shapiro Family Foundation The Daniel Veloric Foundation Legacy Champions for a Cure Robert F. Shapiro Velos Medical Informatics, Inc. Joseph DeVito Nick Adcock Phyllis and Richard Sharlin Mary E. Venable Bernie and Ralph Dunnigan Andrew Akiyoshi Thomas and Madeleine Sherak The Villages Bruce Moore Goedde Max Andes Pam Shriver Fund of the Baltimore Benjamin A. Wade Bruce Alan Hupfer Memorial Sal Augeri Community Foundation Robert and Judy Waller The Estate of Corbin Page The Baggio-Millstein Wedding Herbert J. Siegel David E. Walters Edward M.Piluso Gareth Barlow William Siegel John Walton Estate of Dennis Shea Ray Bayat Adrianne W. Silver Jack L. Warner Edward F. Sulesky Estate Peter Binks Richard Silverman Roger Weber Erlend Bo Ronald A. Simms Raymond J. Weis Michael Cameron David Simon Robert Weiss Damien Clark Dick Simon Jay Weitzman Jeff Dorman Mimi Simoneaux Wheels, Inc. Scott Duxbury Plum and Jonathan Simons Miles D. White Fans of Dan Fogelberg James D. Sinegal Jeffrey S. Wilks Matthew Friend Van Skilling Gary L. Wilson Kimberly Fry Joel E. Smilow Daniel P. Wimsatt Brandon Haley Jeff N. Smith Wolff Family Foundation David Higger Gordon Smith Moira Wolofsky Matthew J. Hoffman Arnold Snider Wolters Kluwer Health Carlo Huber Steve Snyder Kenneth R. Woods David Kimmel Mr. and Mrs. Stuart M. Solomon Working Assets Scott Kolasinski James Soules Rodney A. Wray Ryan Link Sourthern Company Services, Inc. Robert A. Yawitt Brett Matik Southern Wine & Spirits of Nevada, Inc. Bud Yorkin Ray Mays Jerry and Emily Spiegel Family Young Presidents Organization Rebel Bob McKnight Foundation, The Chapter Ryan Nelson Larry Spitcaufsky Gary A. Young Casey Nelson Richard and Ellie Sprague Zenkel Foundation Joseph Nuzzarello Frank P. Stagen Stan Zicklin Nick O’Kane Stak Design, Inc. Ron Zimmerman Ian Parmiter Starbucks Coffee Company Andy Petranek John Stark Propane Industry Pros4Care Starkey Sports Consulting, LLC Steve Rakow The Laura Steinberg Tisch Foundation, Pete Ridge Inc. Will Rutledge Steven E. Stern Kelly Slater The Stone Family Fund Karen Smyers Bonnie and Tom Strauss Neal Thompson Chris Stuhmer Steven Trussell Thomas R. Sturges John M. White Fred and Judith Sullivan Team Winter Mary M. Sullivan Matt Woehnker Suns Legacy Partners, LLC John Yodzis Dennis A. Suskind Pam Zam Don Swirnow S. Jerome and Judith Tamkin Rica F. Tarnoff Janie C. Tarter Fredricka Taubitz and Dennis M. Griffin Walter D. Tearse Terravita Golf Club, Inc. Vincent Tese Chuck B. Thornton, Jr. Steve Tino Tom Tisch TJH James E. Tolson, Jr. Thomas Tonko Judith and Eugene Toombs Stanley S. Trotman, Jr. Cecily Truett Mark Truitt Jeffrey H. Tucker Tuesday’s Children Turner Broadcasting System, Inc. UBS AG Peter V. Ueberroth William D. Unger United Jewish Foundation of Metropolitan Detroit United Way of Greater Los Angeles Tom Unterman Michael J. Urfirer Basil K. Vasiliou

Every effort has been made to ensure completeness and accuracy of this list. If errors or omissions exist, please accept our apologies and call 800.757.CURE (2873). Thank you.

22 Appeal for Support

Dear Friend:

In the past sixteen years, deaths from prostate cancer have been reduced by nearly 40 percent compared to what was once projected, game-changing research programs have delivered promising results, and hope has continued to soar. On behalf of patients, families, caretakers and our PCF

research scientists that serve them, thank you. This progress would be unsustainable without your Report Progress 2008 ongoing support.

Your investment in the Prostate Cancer Foundation (PCF) is wisely deployed. Since 1993, virtually every important discovery in the battle against this disease has been facilitated by PCF funding or coordination. Moreover, every dollar you contribute to the PCF is multiplied 20 to 30 times; our activities set into motion a ripple that spurs research at government, private and charitable institutions and, in effect, leverages the millions of dollars we raise into billions.

You also help us build a dynamic, collaborative community. Sixteen years ago, prostate cancer researchers had no vantage point to comprehend the full scope of others’ efforts. Today, no other organization has a more comprehensive and real-time view of the full prostate cancer landscape and its most promising research than the PCF. Our approach has galvanized the prostate cancer research community and has been a catalyst for accelerating scientific discovery.

Your continued generosity is more important than ever. The need is especially urgent now, with continued pressures on federal budgets and years of flattened research funding from the National Institutes of Health. This challenge to research funding is a serious threat to the momentum we’ve built.

Your donation is vital for us to reach our goal of ending prostate cancer. We appreciate your support and ask that you give now.

With deepest gratitude,

Jonathan W. Simons, MD President and Chief Executive Officer David H. Koch Chair

23 donation opportunities

The Prostate Cancer Foundation welcomes gifts of cash, securities, non-cash assets and gifts by will or living trust. We also welcome contributions made in memory, in tribute or in honor of friends or loved ones.

Donations Other Gift Suggestions

Please mail your check to: •• Assets or property including appreciated stock and real estate Prostate Cancer Foundation 1250 Fourth Street •• Bequest – include a gift to the PCF in your will Santa Monica, CA 90401 •• Name the PCF as the primary or contingent To make an online contribution, please visit our beneficiary on a life insurance policy website: www.pcf.org •• Rollover funds from your IRA as a gift to the If you prefer, you can make a donation by phone PCF and avoid all tax on the rollover (valid by calling toll-free (800) 757-CURE (2873). through December 31, 2009 and applies to those 70-1/2 years and older) Memorial or Tribute Gifts More information: www.pcf.org •• Honor the memory of a loved one or celebrate the accomplishments of a friend or family member by helping others

•• Make a memorial or tribute gift and the PCF will send an acknowledgement card to the family or honoree

Monthly Giving

Set up recurring donations for a convenient and manageable gift process that fits your monthly budget.

24 Prostate cancer foundation Statements of Financial Position

Years Ended December 31 2008 2007

Assets Current assets: Cash and cash equivalents $ 27,894,591 $ 21,275,262 Pledges receivable 4,043,333 6,442,212 Marketable securities 25,312 52,868 Report Progress 2008 Prepaid expenses 80,497 59,216 Other receivables — 50,564 Total current assets 32,043,733 27,880,122

Fixed assets: Furniture and fixtures 37,180 37,180 Office equipment 110,574 110,574 Leasehold improvements 246,891 246,891 Computer Software 344,384 325,280 Total fixed assets 739,029 719,925 Less accumulated depreciation (606,244) (542,457) 132,785 177,468

Investments 960,000 — Long-term pledges receivable 2,772,772 1,236,542 Total assets $ 35,909,290 $ 29,294,132

Liabilities and net assets Accounts payable $ 76,830 $ 366,535 Accrued liabilities 1,377,160 1,546,860 Research awards payable 18,462,755 8,650,000 Total liabilities 19,916,745 10,563,395

Unrestricted net assets 15,992,545 18,730,737 Total liabilities and net assets $ 35,909,290 $ 29,294,132

25 Prostate cancer foundation Statements of Activities

Years Ended December 31 2008 2007

Support and revenues: Donations $ 36,720,708 $ 34,773,813 Net realized and unrealized loss on investments (3,805) (1,578) Interest and other income 520,254 624,047 Total support and revenues 37,237,157 35,396,282

Program services: Research grants, association awards and donations 28,069,538 14,274,150 Scientific conferences 2,086,024 2,420,640 Public awareness and advocacy expense 2,529,047 1,560,191 Total program services 32,684,609 18,254,981

General and administrative expenses 2,887,230 2,420,921 Fund-raising expenses 4,403,510 4,729,126 Total expenditures 39,975,349 25,405,028 Change in net assets (2,738,192) 9,991,254

Net assets at beginning of year 18,730,737 8,739,483 Net assets at end of year $ 15,992,545 $ 18,730,737

26 Prostate cancer foundation Statements of Cash Flows

Years Ended December 31 2008 2007

Operating activities Change in net assets $ (2,738,192) $ 9,991,254 Adjustments to reconcile change in net assets to net cash provided by operating activities: Depreciation and amortization 63,787 63,082 Report Progress 2008 Donation of marketable securities (116,462) (227,158) Net realized and unrealized gain (loss) on investments 3,805 1,578 Proceeds from sales of marketable securities 237,758 225,580 Changes in operating assets and liabilities: Pledges receivable 862,649 3,052,251 Marketable securities (1,057,545) (23,484) Prepaid expenses (21,281) 3,185 Other receivables 50,564 60,034 Accounts payable (289,705) 179,704 Accrued liabilities (169,700) 175,196 Research awards payable 9,812,755 (4,881,870) Net cash provided by operating activities 6,638,433 8,619,352

Investing activities Purchase of furniture, equipment and improvements (19,104) (146,282) Net cash used in investing activities (19,104) (146,282)

Net increase in cash and cash equivalents 6,619,329 8,473,070 Cash and cash equivalents at beginning of year 21,275,262 12,802,192 Cash and cash equivalents at end of year $ 27,894,591 $ 21,275,262

27 Prostate cancer foundation Report of Independent Auditors

Board of Directors Prostate Cancer Foundation

We have audited the statements of financial position of the Prostate Cancer Foundation (the Foundation) as of December 31, 2008 and 2007, and the related statements of activities and cash flows for the years then ended. These financial statements are the responsibility of the Foundation’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Foundation’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Foundation at December 31, 2008 and 2007, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States.

September 23, 2009

28 The MackCompanyThe Partner Senior Mack I. Earle Honorable The LeFrakThe Organization Chief Executive Officer PresidentChairman, and LeFrak Richard Koch Industries Executive Vice President Koch Hamilton David Investor Kern Arthur Cedars Sinai MedicalCenter Prostate Cancer Center Director, Louis Warschaw MD (Skip) Holden, Stuart Milken FamilyThe Foundation Grier Rosey Reverend The LP Bloomberg, Chairman T.Peter Grauer LLC Flintridge Capital Investments, Partner Managing Evensen B. Christian R. Clearinghouse ACS Founder J. Epstein David Ederer Investment Company Chairman Ederer David Safeway, Inc. Chief Executive Officer PresidentChairman, and Burd Steven A. Associates Domain General Partner Blair James CastleNorth Partners Partner Managing F. Jr.Charles Baird, Prostate Cancer Foundation Chairman and Founder Milken Michael Board of Directors BOARD OF DIRECTORS AND LEADERSHIP TEAM Zenith National Insurance Corp. President Chairman and Zax Stanley Stupski Foundation Chairman J. Stupski Lawrence Partida Tequila, LLC Chairman Shansby J. Gary Milken Family Foundation Executive Vice President &Sandler Maron President Vice Sandler Richard Consultant Jr. Roberts, Bert InternationalRoll Vice Chairman Lynda Resnick ShipstonThe Group Vice Chairman Nordhoff Henry Development EJM Partner Monkarsh Jerry Prostate Cancer Foundation President Vice Milken Lori CircleLeaders’ Milken Institute Young Chair and Co-Founder Milken E.J. Private HealthManagement Chief Executive Officer D. Michelson Leslie Aurec Group Director Meitar Shmuel Advisors Crestview Director Managing Marcus A. Jeffrey

Communities-in-Schools National Chairman Resorts Wynn Director Wynn Elaine Triarc Companies, Inc. Chief Executive Officer and Chairman Peltz Nelson Defense of Department U.S. forHealthAffairs Defense Former Assistant of Secretary MD Ward (Trip)S. Casscells, BoardHonorary

Communications President Vice APR Zenka, Dan Operations Development President Vice Wolterstorff Jan Enterprises Sports Baseball and President Vice Dave Perron Finance Administration and President Vice Hsieh Helen Credit Card Program Events, Relations and Donor President Vice Haber Jan Medical Director MD (Skip) Holden, Stuart Chief Science Officer Executive Vice President and PhD Soule, R. Howard Development Executive Vice President Dicovitsky Gary Treasurer Secretary and Chief Financial Officer, Finerman Ralph Koch H. Chair David Chief Executive Officer President and MD W. Simons, Jonathan Leadership Team

2008 Progress Report pcf.org

1250 Fourth Street Santa Monica, CA 90401 Tel 800.757.CURE (2873) Fax 310.570.4701